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Antigen presentation, autoantigens, 
and immune regulation in multiple 
sclerosis and other autoimmune 
diseases
Christine Riedhammer and Robert Weissert*
Neuroimmunology, Department of Neurology, University of Regensburg, Regensburg, Germany
Antigen presentation is in the center of the immune system, both in host defense against 
pathogens, but also when the system is unbalanced and autoimmune diseases like multiple 
sclerosis (MS) develop. It is not just by chance that a major histocompatibility complex 
gene is the major genetic susceptibility locus in MS; a feature that MS shares with other 
autoimmune diseases. The exact etiology of the disease, however, has not been fully 
understood yet. T cells are regarded as the major players in the disease, but most probably 
a complex interplay of altered central and peripheral tolerance mechanisms, T-cell and 
B-cell functions, characteristics of putative autoantigens, and a possible interference of 
environmental factors like microorganisms are at work. In this review, new data on all these 
different aspects of antigen presentation and their role in MS will be discussed, probable 
autoantigens will be summarized, and comparisons to other autoimmune diseases will 
be drawn.
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introduction
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS), causing a loss 
of myelin sheaths and a degeneration of axons preferably in the white matter, but also in the cortex (1).
Despite immense exploratory efforts, the pathogenesis and target antigen(s) of MS have so far 
not or only partially been identified. This problem is also present in other autoimmune disease like 
rheumatoid arthritis (RA) or type 1 diabetes mellitus (T1D). On the other hand, research has revealed 
the targets of other diseases like myasthenia gravis (MG) or neuromyelitis optica (NMO), but their 
exact pathogeneses by the interplay of different immune cells still remain unclear.
Multiple sclerosis is widely thought to be induced and perpetuated by the immune system. T cells 
are believed to have a central role in the pathogenesis of the disease. It is assumed that defects of 
central and peripheral tolerance permit an existence of self-reactive T cells, which are activated by 
antigen-presenting cells (APCs).
As different autoimmune diseases share the feature that risk is conferred by genes that are encoded 
within the major histocompatibility complex (MHC) locus, antigen presentation generally seems to be of 
great importance in autoimmune diseases. This review will point out important mechanisms of antigen 
presentation, autoantigens as well as the contribution of different types of immune cells in autoimmune 
diseases. The focus will be on MS, but other autoimmune diseases like RA, T1D, MG, NMO, and 
autoimmune encephalitides (AE) will provide comparisons concerning the genetic background, the 
ambiguity of the identified or suspected target antigens, and the underlying pathogenic mechanisms.
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Antigen Processing
Peptide fragments that are presented on MHC class I or MHC 
class II molecules are first processed within the cell before they 
reach the cell membrane on the respective MHC molecule (2). 
The processing machineries for MHC class I and MHC class II 
molecules differ. Peptides derived from the cytosol and the nucleus 
are presented on MHC class I molecules. For their processing, the 
proteasome is of paramount importance. Inhibition of proteasomal 
function can block antigen presentation (3). Interferon (IFN)-γ can 
induce the immunoproteasome, which leads to the processing of a 
different set of peptides compared to the constitutive proteasome 
(4). Apart from the proteasome, also the endoplasmic reticulum 
(ER) is important for the presentation of peptides on MHC class I 
molecules. Specialized aminopeptidases are involved in trimming 
the peptides to a length of 8–10 amino acids (5, 6). Peptides are 
subsequently loaded on MHC class I molecules. In this process, 
tapasin and the transporter associated with antigen processing 
(TAP) are involved, which are expressed in the ER (7). The binding 
groove of MHC class I molecules is closed, limiting the length of 
the presented peptides to 8–10 amino acids, even though examples 
of longer peptides presented on MHC class I molecules exist (8).
Major histocompatibility complex class II molecules bind 
antigens that are derived from extracellular proteins. These are 
taken up by endosomes and subsequently processed. The pH 
in the endosomes is very important for the control of protease 
activity (9). The binding grooves of MHC class II molecules in 
the endosomes are normally covered by the invariant chain (10). 
A specific part of the invariant chain (the CLIP) covers the groove 
and can be removed by human leukocyte antigen (HLA)-DM (11). 
Subsequently, peptides that are present in the endosomes can bind 
in the groove and be presented to T cells. The binding groove 
of MHC class II molecules is open and presented peptides are 
generally 14–18 amino acids in length. Under certain conditions, 
however, also shorter or longer peptides can be presented. While 
MHC class I molecules are present on all nucleated cells, MHC 
class II molecules are only present on specialized APCs like den-
dritic cells (DCs), B cells, and macrophages. In the CNS, microglia 
are considered as professional APCs (12). Also, astrocytes can 
present antigen on MHC class II molecules under certain condi-
tions (13). Since the uptake of antigen differs between different 
types of professional APCs, also the presented set of peptides can 
differ. In addition, also the intracellular composition of molecules 
differs regarding the antigen processing machinery (14).
There is cross-presentation of antigens in the MHC class I 
and MHC class II pathway (15, 16). Different pathways allow 
this cross-presentation. Phagosomes that take up antigen from 
the extracellular space can have ER-associated molecules. Also 
certain immunopeptidases contribute to cross-presentation (17). 
Cross-presented antigens from extracellular origin are mainly 
presented on MHC class I molecules of DCs (18).
In regard to autoimmune diseases, the exact sequence of events 
leading to the presentation of certain sets of autoantigen-derived 
peptides on APCs in humans is still incompletely deciphered. 
Potentially, all molecules involved in antigen processing and 
binding of autoantigens to MHC molecules might influence the 
emergence of autoimmune disease. Even though the role of the 
different steps in antigen processing in autoimmune diseases has 
not been fully established yet, much will be learned over the next 
years and be of potential importance for the design of new therapies.
Tolerance
The emergence of an autoimmune disease apparently requires the 
existence of self-reactive cells which escape central and peripheral 
tolerance mechanisms and become activated in some way. Self-
reactive T cells have been shown to be present both in persons with 
and without autoimmune disease (19–26). How self-tolerance is 
disrupted in autoimmune disease, however, remains to be ascer-
tained. The understanding of how tolerance mechanisms work is 
also the basis for a comprehension of potential deficiencies.
Central Tolerance
The challenge of intrathymic central tolerance induction includes 
tolerizing T cells reactive with antigens which are not expressed 
ubiquitously, but only found in particular organs (tissue-restricted 
antigens, TRAs). The intrathymic expression of TRAs can induce 
tolerance and prevent development of autoimmune disease (27). 
This is achieved by negative selection of T cells in the thymic 
medulla, where T cells exhibiting a high affinity/avidity interac-
tion between their T-cell receptor (TCR) and MHC–self-peptide 
complexes presented by medullary APCs become apoptotic. 
Medullary thymic epithelial cells (mTECs) and DCs cooperate 
to achieve this (28). The thymic transcription factor autoimmune 
regulator (AIRE) plays a fundamental role in central tolerance 
induction, as it controls the transcription of genes coding for TRAs 
(29), and is predisposed, when not working properly, to favor the 
development of autoimmune disease. Certain single nucleotide 
polymorphisms (SNPs) in the AIRE gene have been suggested 
to play a role in autoimmune diseases like RA or MG (30–32). 
Interestingly, mTECs make use of macroautophagy for presenting 
antigens also on MHC class II molecules, which enables them to 
tolerize CD4+ T cells (33). Important candidate autoantigens of MS 
and other autoimmune diseases seem to be present in the human 
thymus (34–36). Consequently, a lack of presentation of important 
self-antigens in the thymus cannot fully account for the existence 
of autoreactive T cells.
Apart from thymocytes recognizing a peptide that is only rarely 
presented in the thymus, also thymocytes expressing a TCR whose 
affinity/avidity for a peptide–MHC complex is too low to eliminate 
the thymocytes during negative selection are thought to be able to 
elude central tolerance mechanisms (37).
Post-translational modifications of self-antigens in the periph-
ery can also change the affinity/avidity of the interaction between 
a TCR and a self-peptide–MHC complex. Thus, the affinity/avidity 
between a TCR and a self-peptide–MHC complex might be low 
enough to avoid central tolerance induction, but high enough to 
lead to an activation of autoreactive T cells in the periphery after 
a post-translational modification of the antigen. For example, 
thiopalmitoylation occurs frequently with proteolipid protein 
(PLP), a putative autoantigen in MS, and it was found that post-
translationally modified PLP is more encephalitogenic than the 
unmodified form (38). Also citrullinated proteins were found more 
frequently in MS lesions than in control brain tissue (39).
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Another interesting aspect is the structural nature of the inter-
action between a TCR of a potentially self-reactive T cell and its 
respective peptide–MHC complex in the thymus. An analysis of 
the crystal structure of a TCR and a self-peptide–MHC complex 
in an MS patient showed that the TCR bound in a tilted way to 
the peptide–MHC complex (40). Such structural deviations might 
result in a low affinity/avidity of the interaction between TCR 
and self-peptide–MHC complex, so that the T cell can escape 
from central tolerance. In the periphery, however, the quantity of 
self-antigen is higher and the affinity/avidity might then be high 
enough to contribute to the pathogenesis of autoimmune disease. 
It was shown that autoreactive T-cell clones both in MS and T1D 
exhibited a lower recruitment of self-peptide–MHC complexes 
than T cells from the same patients specific for viral peptides. 
Nevertheless, the autoreactive T-cell clones proliferated vigorously 
in response to self-antigen, indicating that TCR signaling is still 
functional in these cells (41). Again, these facts might support an 
escape of negative selection and a possible activation of these cells 
in the periphery.
Peripheral Tolerance
When self-reactive T cells escape central tolerance mechanisms, 
peripheral tolerance mechanisms are required, which include 
ignorance, i.e., the physical separation of autoreactive cells and 
their target, the deletion of autoreactive cells, their inhibition, 
e.g., by a lack of costimulatory factors and their suppression by 
regulatory T cells (42).
An important factor for the inhibition of T cells is the 
function of the cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4 = CD152). Its role in MS has been investigated in many 
studies. A recent meta-analysis of genetic polymorphisms of 
the CTLA-4 gene did not reveal any associations with MS (43). 
However, there are several studies pointing toward a significance 
of costimulatory mechanisms for MS. Myelin-reactive T cells 
from MS patients were observed to be less sensitive to a lack of 
costimulation than T cells from controls (44–46). Also, another 
study found increased T cells insensitive to costimulation in MS 
patients, which predominantly produced Th1 cytokines (47). In 
active MS, increased CD80+ cells were found (48).
An important mechanism for the deletion or “activation-
induced cell death” of autoreactive cells is the interaction of Fas 
and Fas ligand, which can induce apoptosis in autoreactive T cells. 
A higher resistance of T cells to apoptosis in MS patients has been 
reported in several studies which found decreased expression of 
Fas and a lower rate of apoptosis induced by stimulation with 
mitogen in T cells from MS patients (49, 50). New data indicate that 
Th1 cells seem to be more susceptible for Fas-mediated apoptosis 
than Th17 cells, both in MS patients and healthy controls (51).
Regulatory T cells are probably the most important contribu-
tors to the maintenance of peripheral tolerance. They are mainly 
defined by the expression of the transcription factor Foxp3 (52). 
Foxp3+ regulatory T cells are able to suppress proliferation of 
CD4+CD25− T cells (52, 53). It was found that interactions of 
thymocytes with MHC class II molecules expressed by mTECs 
were important for the induction of regulatory T cells (54). The 
possible role of different regulatory cell types in MS is discussed 
below in the respective sections.
immune Pathogenesis
The CNS as the target organ of the autoimmune response in MS is 
a special one. It is only a short time ago that it was recognized that 
the CNS is physiologically supervised by immune cells. Thereby, 
memory T cells are thought to play an important role (55).
It is believed that myelin-specific T cells have a crucial role in 
the pathogenesis of MS (56). Naïve myelin-specific T cells, which 
cannot access areas outside the secondary lymphoid tissues (57), 
are thought to be activated in the periphery, gain access to the 
CNS, and then be reactivated by CNS-resident cells presenting 
self-antigen (37). The CNS is extraordinarily shielded from the 
periphery by the existence of the brain–blood barrier (BBB) and 
the brain–cerebrospinal fluid (CSF) barrier. For activated T cells, 
there are three routes to enter the CNS, i.e., by crossing the BBB or 
the blood–CSF barrier or by migrating through the carotid arteries 
into the subarachnoid space (58). The most important pathogenic 
mechanisms in MS are outlined in Figure 1.
Peripheral Activation of T Cells
How T cells specific for CNS antigen are activated in the periphery 
remains unclear. However, their activation could result from a 
trigger by an infectious agent or from the presentation of myelin 
antigens in the cervical lymph nodes (37). Concerning the latter 
mechanism, CSF is drained via the nasal lymphatic system to the 
cervical lymph nodes. In experimental autoimmune encephalo-
myelitis (EAE) induced in marmosets, a relevant animal model of 
MS, myelin components were detected to be increased in APCs 
in cervical lymph nodes (59). A study using fine-needle biopsy 
material of cervical lymph nodes of MS patients and controls 
also detected more macrophages containing myelin basic protein 
(MBP) and PLP in MS patients than in controls (60). Therefore, 
APCs presenting myelin fragments in the cervical lymph nodes 
might contribute to an activation of naïve self-reactive T cells.
Role of infectious Agents
Apart from this concept, also infectious agents are considered to 
play an important role in triggering autoimmune diseases. In this 
context, a cross-talk between the innate and adaptive immune 
system might be relevant: infectious agents can activate APCs 
via Toll-like receptors (TLR). APCs can then contribute to the 
activation of self-reactive T cells (61).
Structural similarities between antigens of infectious agents 
and myelin proteins (molecular mimicry) can induce an activation 
of naïve autoreactive T cells which recognize peptides derived 
from infectious agents and self-antigens. Novel data indicate 
that cross-reactivities do not necessarily require nearly identical 
amino acid sequences. They also occur when some important 
motifs are conserved which make sure the overall structures of 
TCR–peptide–MHC interaction are similar (62). This suggests that 
cross-reactivities may happen frequently. There has been intensive 
research on possible infectious triggers of MS: it has been shown 
that T-cell clones specific for an immunodominant epitope of MBP, 
namely MBP85–99, also recognize viral peptides, e.g., of Epstein 
Barr virus (EBV), influenza A virus, herpes simplex virus, human 
papilloma virus (63), or human herpesvirus-6 (64). Concerning 
EBV, for example, MS patients seem to exhibit higher antibody 
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titers against certain antigenic components of the virus than 
controls even before the onset of MS (65). In EAE experiments, it 
could also be shown that a peptide from H. influenzae mimicking 
a PLP-peptide can actually induce CNS disease (66).
In the context of molecular mimicry, also self-mimicry has 
been observed. Transgenic myelin oligodendrocyte glycoprotein 
(MOG)-deficient mice expressing a MOG-specific TCR develop 
EAE due to a cross-reactivity between a MOG epitope and neu-
rofilament NF-M (67). Such cross-reactivities could play a role in 
the induction of axonal damage also in human MS.
Independently from cross-reactivities, infectious agents can 
lead to a disruption of tolerance to self-antigens by bystander 
activation. For example, demyelination can be induced when 
certain immunodeficient (RAG2−/− transgenic) mice are infected 
with mouse hepatitis virus (MHV), even though the CD8+ T cells 
they possess are neither specific for MHV nor for CNS antigen, 
when their T cells are activated by the antigen they recognize (68).
Recently, besides molecular mimicry and bystander activation, 
another interesting mechanism has been proposed: myelin-specific 
CD8+ T cells expressing a dual TCR specific for both MBP and viral 
antigens have been discovered. The activation of such T cells during 
viral infection might also induce autoimmune reactions (69).
Besides infectious agents, commensal microbiota could be 
of importance in the pathogenesis of the disease. EAE in mice 
expressing a transgenic TCR for MOG was found to depend on 
the presence of the commensal gut flora (70).
epitope Spreading
During the course of an autoimmune disease, otherwise physi-
ological immunological mechanisms like epitope spreading set 
in, which contribute to the perpetuation and diversification of 
the ongoing immune response. Epitope spreading means the 
expansion of the immune response to epitopes that are different 
from the initially targeted ones. This process is physiological 
and helpful in the fight against pathogens, but it also seems 
FiguRe 1 | Pathogenesis of MS. The exact pathogenesis of MS is not clear 
yet. However, it can be imagined that naïve autoreactive T cells exist because 
of imperfections in central and peripheral tolerance mechanisms. They might 
then become activated by antigen presentation in cervical lymph nodes or 
effects of molecular mimicry. Antigen presentation on disease-associated 
HLA-DR15-molecules might influence both the emergence and activation of 
autoreactive T cells. When autoreactive T cells reach the CNS by crossing the 
BBB, they encounter their target antigen and start an inflammatory cascade, in 
which other antigens become unveiled, triggering the process of epitope 
spreading.
to play an important role in the emergence of autoimmune 
responses.
In EAE, it could be shown that the immune response is first 
focused on a certain epitope and then spreads to other epitopes 
during the chronification of the disease (71, 72). Apart from intra-
molecular epitope spreading (e.g., within different MBP epitopes), 
also intermolecular epitope spreading, e.g., from MOG to MBP, has 
been observed in different EAE models (71, 73, 74). In different 
animal models of MS, it could also be shown that epitope spreading 
can begin in the CNS (75). Interestingly, also in an animal model 
using the CNS-resident virus Theiler’s murine encephalomyelitis 
virus for disease induction, T-cell reactivities against certain 
myelin epitopes emerged during the course of the disease, which 
were not due to molecular mimicry (76). Epitope spreading was 
reported to be associated with clinical relapses in animal models, 
as T cells reactive with epitopes the immune response had spread 
to could induce disease in other animals (74).
Both intramolecular (24, 25, 77–79) and intermolecular (80) 
epitope spreading has been observed in MS patients as well. 
However, it remains to be proven that this process also plays a 
pathogenic role in the disease, as some studies could not detect 
any associations with clinical exacerbations (77, 78).
Epitope spreading is also involved in other autoimmune 
diseases, complicating the search for the initial target antigens of 
the autoimmune response and complicating also the development 
of potent therapies which should ideally operate in all or many 
patients. Further understanding of this process will be crucial for 
designing efficient therapies.
immune Cells involved in the 
Pathogenesis of MS
Role of CD4+ T Cells
CD4+ T cells are widely considered major players in the patho-
genesis of MS.
FiguRe 2 | CD4+ T-cell differentiation. Naïve CD4+ T cells can differentiate 
into different T helper cell subsets. In MS, Th1 and Th17 cells are regarded to 
be disease-promoting, whereas regulatory T cells and Th2 cells seem to exert 
a protective effect. The exact role of Th9 and Th22 cells remains to be further 
clarified. Th1 cells, which predominantly produce TNF (95), IFN-γ, IL-2 (332), 
and lymphotoxin-α (333), are induced by IL-12 (95). Their master regulator is 
the transcription factor (TF) T-bet (334). They mainly interact with cytotoxic 
CD8+ T cells and macrophages (335). Th2 cells, which mainly interact with B 
cells (335), are induced by IL-4 and secrete IL-4, IL-5, IL-6, and IL-10 (101, 
333, 335). GATA-3 is the most important TF of Th2 cells (336). IL-6, TGF-β 
(93), and IL-23 (95) are important cytokines for the induction of Th17 cells 
producing IL-17, IL-6, TNFα (95), IL-21 (94), IL-22 (337). RORγt is the master 
regulator of this T-cell subset (338). Interestingly, TGF-β is also necessary for 
the induction of regulatory T cells, whereas IL-6 must be absent in this case 
(93, 117). The master regulator for the induction of regulatory T cells is the TF 
Foxp3 (52, 339). Regulatory T cells then produce TGF-β and IL-10 (117). 
Recently also Th9 cells and Th22 have been identified to be a discrete T-cell 
subset. The induction of Th9 cells is promoted by IL-4 and TGF-β (340). Th9 
cells produce IL-9 and to a lesser extent IL-10 (340, 341). Under the influence 
of TGF-β, Th2 cells can switch their phenotype and become Th9 cells (342). 
Master regulators for Th9 and Th22 cells have not been identified so far. 
Important factors for the induction of Th9 cells are PU.1, IRF, BATF, different 
STAT factors, and TGF-β-induced SMADS (341, 343). Priming of IL-22 
producing Th22 cells is promoted by IL-6 and TNF (103). The transcription 
factor aryl hydrocarbon regulator (AHR) seems to exert an important influence 
on IL-22 production (344).
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This is in part due to the fact that most of the genetic susceptibil-
ity for MS is associated with certain MHC class II alleles (81). CD4+ 
T cells have also been detected in MS lesions (82). Evidence also 
comes from a humanized mouse model: transgenic mice express-
ing the MS-associated DR2-molecule (DRA*0101/DRB1*1501), 
an MBP-specific TCR derived from MS patients and human CD4 
develop disease with symptoms very similar to those in MS and 
more severe symptoms than mice lacking CD4 expression (83). 
It is not clear yet, which CD4+ T helper cell subset (Th cell) exerts 
the most important influence on the disease. The subsets which 
are discussed most are Th1 cells and Th17 cells. Figure 2 gives an 
overview of different T-cell subsets, their signature cytokines, 
and important transcription factors.
Th1 Cells
Th1 cells have been and are seen as causative agents in MS, since 
MS-resembling animal models are driven by this T helper cell 
subset. There is also evidence that this T-cell subset might play a 
major role in human MS.
Administration of an altered peptide ligand (APL) based on 
an immunodominant epitope of MBP led to cross-recognition of 
MBP and the APL, resulting in exacerbations in some patients. 
The phenotype of the reactive T cells was skewed toward Th1 (84). 
Also other studies showed (partly by determination of chemokine 
receptor expression) that Th1 cells are especially increased in MS 
patients suffering a relapse compared to healthy controls or patients 
in remission (85–87). In PLP-specific T-cell lines isolated from 
MS patients during acute attacks, Th1 cytokines were found to be 
dominant (88) and also MBP-specific T-cell lines in MS patients 
produced significantly more IFN-γ than T-cell lines from controls 
(89). A correlation between IFN-γ-secretion (after stimulation with 
phytohemagglutinin) and contrast-enhancing lesions in MR was 
also detected (90). Higher levels of myelin-specific high-avidity 
CD4+ T cells were found in MS patients than in healthy controls, 
which exhibited a Th1 phenotype and higher IFN-γ production 
in MS patients (91). Recently, EAE experiments showed that Th1 
cells first infiltrate the CNS and are suppressed by regulatory T 
cells, which stops progression of the disease, whereas Th17 cells 
infiltrate the CNS later during the disease course (92).
Th17 Cells
In the last years, interleukin (IL)-17 producing Th17 cells have 
moved to the focus of research. Important factors for the induction, 
differentiation, and maintenance of the Th17 cell repertoire are 
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IL-6, transforming growth factor (TGF)-β (93), IL-21 (94), and 
IL-23 (95). IL-23-deficient mice have been shown to be unable to 
develop EAE (95). Interestingly, the development of regulatory 
T cells also requires TGF-β in the absence of IL-6 (93). IL-17 
transcripts have been shown increased especially in chronic silent 
MS lesions (82) and IL-17 positive cells were also found increased 
in MS lesions (96). In MS patients, more Th17 cells have been 
detected than in healthy controls and NMO patients (97). A study 
investigated T-cell subsets in patients with an aggressive disease 
course who received high-intensity chemotherapy followed by 
autologous stem cell transplantation, which induced remission 
in all patients. Interestingly, Th17 cell numbers were still decreased 
1 year after transplantation, whereas Th1 cells had reached normal 
levels, which might speak for an association between the decreased 
Th17 cells and the remission (98). Higher IL-17 production by 
myelin-reactive T cells has been reported in MS patients than in 
controls (99).
Th9 Cells and Th22 Cells
Recently, novel T-cell subsets have been detected whose role in 
MS has already begun to be investigated: Th9 cells reside mainly 
in the skin, where IL-9 might also play a role in the production of 
other cytokines like IFN-γ, IL-13, or IL-17 by T cells in the skin 
(100). Besides Th1 and Th17 cells, also Th9 cells could be shown 
to induce a milder form of EAE (101).
Similar to Th9 cells, Th22 cells were identified as a distinct T-cell 
subset to be present in the skin a few years ago (102, 103). Increased 
fractions of (myelin-reactive) Th22 cells have been reported in 
MS patients (104).
Regulatory T Cells
In MS patients, there does not seem to be a reduction of regulatory 
T cells in number (105–110), but there is some evidence that regu-
latory T cells might suppress autoreactive T cells less efficiently 
compared with healthy controls: regulatory T cells from MS 
patients seem to be less able to suppress effector T cells (106–108, 
110–112) and have a lower cloning frequency than regulatory 
T cells from healthy controls (106). However, it must be stated 
that some of these studies assumed the CD4+CD25hi phenotype 
as characteristic for regulatory T cells. However, after Foxp3 had 
been discovered, it became clear that by far not all regulatory 
T cells express CD25 at high levels (53). New regulatory T cells 
either mature in the thymus or stem from an expansion of regula-
tory T cells in the periphery. The latter mechanism physiologically 
gains importance with increasing age. In MS patients, there seems 
to be a selective lack of regulatory T cells released from the thymus, 
to which the observed functional impairment might be ascribed. 
The difference in thymic release of regulatory T cells between 
MS patients and healthy controls vanishes with increasing age of 
patients and controls (113–115). This might also partly explain 
why a functional impairment of regulatory T cells was detected in 
(younger) MS patients with relapsing-remitting disease (RR-MS) 
but not in (older) patients with secondary-progressive MS (SP-
MS) (109). Interestingly, Th17 cells can only be suppressed by a 
special subset of regulatory T cells expressing CD39, which were 
found reduced in number and less functional in RR-MS patients 
(but not in SP-MS patients) (116).
In EAE experiments, different observations concerning the 
function of regulatory cells during relapses were made: a study 
observed that regulatory T cells succeeded in suppressing naïve 
splenic autoreactive T cells, but not effector T cells from the CNS 
(in a cytokine milieu containing IL-6 and TNF) at the peak of 
disease (117). In another EAE study, however, regulatory T cells 
were found fully functional also during the peak of disease and 
were shown to alleviate disease by a putative suppression of Th1 
cells (92). Similarly, human T cells showed an enhanced expression 
of genes responsible for suppression of IFN-γ (118). These findings 
might indicate that during acute attacks the immune system starts 
a counterregulation, which might lead to remission. Interestingly, 
regulatory T cells were found increased in the CSF of MS patients 
compared to controls regardless of an active or inactive disease 
state (108). In a study investigating autoimmune responses after 
bone marrow transplantation in rats at the peak of EAE, an induc-
tion of regulatory T cells was shown, which are probable to make an 
important contribution to the achieved remission observed (119).
Role of CD8+ T Cells
Recently, also CD8+ T cells have drawn more attention. They are 
more frequently encountered in MS lesions than CD4+ T cells 
(120). CD8+ T-cell clones detected in brain lesions were shown 
to be still present in blood and CSF after several years (121). 
Another fact supporting the pathogenic role of CD8+ T cells is that 
MHC class II molecules interacting with CD4+ T cells are mainly 
expressed on professional APCs. However, MHC class I molecules 
are expressed on all nucleated cells, including oligodendrocytes 
or astrocytes and CD8+ T cells can interact with peptides bound 
to the MHC-I complex. In this context, CD8+ T cells were shown 
to be able to cause axonal damage (122). Increased reactivities of 
MBP-specific CD8+ T cells were shown to be present in MS patients 
compared with healthy controls. The CD8+ T cells identified by this 
study were predominantly memory T cells (CD45RO+) (123). An 
increased proportion of memory CD8+ T cells was also reported 
in the CSF of MS patients (124, 125). Elevated levels of granzyme, 
which is released by cytotoxic T cells, were found in the CSF of 
patients during relapse (126). So far, many attempts have failed 
to demonstrate stable disease-relevant CD8+ T-cell expansions to 
specific CNS-derived antigens in blood from MS patients. This is in 
contrast to some interesting studies in EAE, in which the relevance 
of myelin-specific CD8+ T cells has been shown. Importantly, CD8+ 
T cells specific for MBP can mediate a form of EAE in which a 
predominance of lesions is seen in the brain rather than in the 
spinal cord and less inflammation can be observed than in classical 
EAE (127).
On the other hand, also regulatory autoantigen-specific CD8+ 
T-cell populations exist, which are able to destroy pathogenic CD4+ 
T cells or mediate a suppression of their proliferation by interacting 
with DCs. Interestingly, these suppressive capabilities were found 
to be reduced during relapses (128–130).
Role of B Cells
Even though T cells are widely believed to play the central role in the 
pathogenesis of MS, there is also evidence supporting a pathogenic 
role of B cells. The importance of a possible role of B cells in MS is 
reflected in a study with rituximab, a B-cell depleting anti-CD20 
FiguRe 3 | The role of B cells in MS. B cells can play a role in autoimmune 
disease by different mechanisms which are depicted here: they can secrete 
potentially pathogenic antibodies, but also their function in cellular immune 
mechanisms are of importance, either by secreting proinflammatory cytokines 
and thereby influencing other immune cells or by acting as antigen-presenting 
cells. After B cells have encountered their specific antigen, they process it, 
present it on MHC and can become activated. As they are able to expand 
clonally, they are then capable to activate a big number of T cells.
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monoclonal antibody (mAb), which was effective in reducing both 
lesion load measured by MRI and clinical relapses (131). The role 
of B cells in MS is schematically depicted in Figure 3.
Most MS patients show IgG oligoclonal bands in their CSF, 
indicating a local antibody production in the CNS (132). However, 
the targets of these locally produced antibodies have not yet been 
fully revealed. MOG-specific autoantibodies have been discovered 
in acute lesions of MS patients (133, 134).
Apart from their ability to secrete antibodies, the cytokines 
secreted by B cells can also influence T-cell proliferation in MS 
patients (135). A further important aspect in their role in cellular 
immunity is that they can serve as APCs (136). Their ability to 
expand clonally allows them to activate many T cells. In an EAE 
model depending on B and T cells, the functions of B cells as 
APCs were shown to be necessary for the induction of EAE instead 
of their ability to secrete antibodies (137). Memory B cells from 
RR-MS patients were shown to induce an increased response of 
CD4+ T cells to myelin antigens compared to memory B cells from 
healthy controls, also pointing toward a role of B cells as APCs 
(138). Clonally expanded B cells have been detected even in the 
CNS of recently diagnosed MS patients (139). Another interesting 
aspect concerning B cells as professional APCs is that the B-cell 
receptors (BCR) consisting of membrane-bound antibodies mostly 
recognize conformational epitopes of a protein, whereas T cells 
recognize linear peptides, processed before by APCs (140). The 
epitopes of an antigen presented by B cells might therefore be 
different from those presented by thymic epithelial and DCs, 
including the possibility that T cells specific for epitopes presented 
by B cells might escape central tolerance induction more easily.
Defects in peripheral (but not central) B-cell tolerance have 
been reported in MS patients, whereas, interestingly, defects in 
both peripheral and central B-cell tolerance have been detected 
in RA and T1D patients (141).
There are also B cells which can adopt regulatory functions, e.g., 
IL-10-secreting B cells, which can inhibit cytokine secretion (142). 
The induction of these IL-10-secreting B cells has been found to 
depend on the presence of IL-21 (which can be secreted, e.g., by 
Th17 cells) and CD40-dependent cognate interactions with T cells, 
whereas it can be inhibited by the presence of IFN-γ and TGF-β 
(143). It is not fully clear yet if the regulatory function of B cells 
might be defective in MS. Data on a possible reduction of IL-10-
secreting B cells in MS patients are contradictory, which is probably 
also due to different study designs (144–146). Interestingly, parasite 
infection with helminths in MS patients can induce these IL-10-
secreting regulatory B cells (147).
Role of Other Professional APCs
Apart from B cells, also other types of APCs have been shown to be 
of importance for antigen presentation in MS. Most work regarding 
the role of APCs in inflammation of the CNS has been conducted 
in rodent models. Unfortunately, the knowledge about APCs in 
human MS is still incomplete and not all gathered knowledge can 
be translated from rodents to humans. DCs are very important for 
linking innate and adaptive immune responses. Different types 
of DCs have been described in humans, namely the blood DCs 
plasmacytoid (p)DC (BDCA2), CD141+ DC (BDCA3), and CD1c+ 
(BDCA1), as well as the skin DCs, the Langerhans cells, and CD14+ 
DCs and inflammatory DCs in non-lymphoid tissue (148). All 
types are capable of presenting antigen, but differ in their expres-
sion pattern of molecules, migratory activity, cytokine secretion, 
and capacity for antigen presentation (149). For example, human 
CD141+ DC (BDCA3) express mainly TLR3, human CD1c + DC 
(BDCA1) mainly TLR2 and pDC (BDCA2) mainly TLR7 and 
TLR9 (150). This leads to different capabilities to react to certain 
pathogens in the environment. TLR stimulation itself results in DC 
maturation (151). DCs are required for the priming of naïve T cells 
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(152). Also the capability to cross-present antigen differs between 
different types of DCs (153). Even though DCs are obviously very 
important for the immunopathogenesis of MS, so far only limited 
data are available (154). Also macrophages have been shown to 
be capable to present antigen in MS (155). In rodent models, 
perivascular phagocytes in the CNS which present CNS antigens 
to T cells are of paramount importance in lesion development 
(156). Such cells can also be found in human MS (157). Within the 
CNS, microglia can serve as professional APCs (158). A change 
in the activation pattern of microglia is already seen very early in 
MS, which could potentially also speak for an increased capacity of 
antigen presentation (159, 160). Also astrocytes can express MHC 
class II molecules under certain conditions and present antigens in 
rodents (13, 161). In humans, so far the role of astrocytes in antigen 
presentation in CNS inflammation is still incompletely defined.
genetics of Multiple Sclerosis
Multiple sclerosis is not a classical hereditary disease. It is rather 
defined as a complex genetic disease. This is supported by twin 
studies, in which for monozygous twins the concordance rate is 
around 30%, and by findings in siblings of affected individuals 
who carry a risk of about 2% (162). Most probably, a combination 
of genetic and also environmental risk factors like smoking (163) 
contributes to its pathogenesis.
More than 100 risk loci have been identified so far in genome-
wide association studies (164), among which the variations 
within the HLA complex play the most important role. The 
most significant gene codes for the MHC class II, DR (81). The 
haplotype HLA-DR2 confers the largest part of the genetic risk 
for MS in Caucasians. In this MS-associated haplotype, two 
HLA-DRβ-chains (HLA-DRB1*1501 and HLA-DRB5*0101) 
pair with the α-chain HLA-DRA*0101, resulting in two heter-
odimers DR2a (HLA-DRA*0101, HLA-DRB5*0101) and DR2b 
(HLA-DRA*0101, HLA-DRB1*1501) expressed on the surface of 
APCs. In this haplotype, three alleles are in linkage disequilib-
rium and therefore mostly inherited together: HLA-DRB1*1501, 
HLA-DRB5*0101, and HLA-DQB1*0602 (165). Among these 
three alleles, HLA-DRB1*1501 confers the greatest genetic risk 
for MS. Other alleles with increased risk are HLA-DRB1*0301, 
HLA-DQB1*0201, HLA-DRB1*1303 (81). An association of the 
HLA-DR15 haplotype in MS with younger age at disease onset was 
reported, but no correlations with the clinical course, prognosis, 
or disease type could be detected (166). In contrast, some HLA-A 
alleles can be attributed some protective effect, most notably the 
allele HLA-A*0201, but also HLA-A*6801, HLA-A*0205, and 
HLA-A*0206 have recently been identified as protective (81). 
The expression of HLA-A*0201 in a humanized transgenic mouse 
model also protected animals from developing disease, possibly 
by influencing negative selection processes in the thymus (167).
Apart from the variations in the MHC-locus, 110 other risk-
conferring genes have been identified up to now in genome-wide 
association studies (164). Interestingly, a magnitude of them are 
genes related to the immune system, which corroborates the hypoth-
esis that MS is an autoimmune disease. Only some important genes 
can be discussed here. Genes regulating IL-2 signaling, which plays a 
pivotal role in T-cell activation, have been proposed to be associated 
with MS, e.g., the IFL-3 gene which regulates IL-2 expression by T 
cells, but also associations with the IL-2 receptor have been described 
(81, 164). Concerning the cytokine pathway, also genes coding for 
IL-7 and its receptor have been linked with a higher risk for MS. Less 
suppressive effects of regulatory T cells in MS patients was observed 
in the presence of cells expressing IL-7Rα (110), providing a possible 
link between the associated gene and a possible function in the 
disease. Also associations with genes coding for molecules involved 
in the costimulatory pathway like CD40 or CD80 have been detected. 
The possible role of defects in this mechanism has been discussed 
above. Several genes coding for signal transduction molecules (like 
STAT-3) have been described as well, which are highly relevant for 
immune cell function. There are also genes related to environmental 
risk factors such as vitamin D (e.g., CYP27B1) (81).
Table 1 shows some of the susceptibility loci of MS, RA, T1D, 
and MG in comparison. Even though this list is by far not exhaus-
tive, some interesting aspects can be comprehended: associations 
with MHC molecules are found not only in MS, but also in RA, 
T1D, MG, and other autoimmune diseases (168–171). There are 
also genes coding for molecules involved in similar costimulatory 
pathways like CD86 or CTLA-4, which contribute to the strength 
of the peptide–MHC interaction, or for cytokine pathways like 
IL2RA or TNF in the respective diseases (81, 168). This shows that 
there may be similar genetic traits leading to the development of 
different autoimmune diseases.
Genetic studies are able to reveal potential associations of cer-
tain genes with autoimmune diseases, but subsequent functional 
studies are necessary to determine the functional relevance of the 
identified genes. The functional relevance of most of the genes 
associated with different autoimmune diseases still remains to be 
clarified.
The relatively strong association of genes coding for MHC 
molecules with different autoimmune diseases suggests that the 
respective genetic variants might affect antigen presentation in a 
way that the emergence of an autoimmune disease is facilitated. 
Structural analyses of the MHC loci in different autoimmune 
diseases revealed certain characteristics of the binding groove, 
potentially leading to a preferential presentation of certain peptides 
(171). In general, MHC class II molecules are involved both in 
negative selection in the thymus by presentation of self-peptides 
and in antigen presentation in the target tissue. However, the exact 
mechanisms how risk is conferred by the MHC molecules still 
remain sketchy. An interesting new aspect was recently observed: in 
HLA-DR15+ individuals, increased autologous T-cell proliferation 
was found. In addition, the authors discovered that the HLA-DR15 
risk allele in MS is presented on itself, suggesting a possible role of 
this haplotype as an autoantigen and as a contributor to autologous 
proliferation (172). Interestingly, also in RA, DRB1*0401-β-chain-
peptides were found to be presented by themselves (173).
A future further understanding of the risk-conferring mecha-
nisms of the HLA genes will provide important new insights into 
the pathogenesis of the respective autoimmune diseases.
Discussed Autoantigens in MS
Principally, possible candidate autoantigens in MS include myelin 
antigens, neuronal antigens, and astrocyte-derived antigens. So 
TABLe 1 | Susceptibility genes in different autoimmune diseases.
Risk locus Function of associated gene/remarks Reference
Multiple sclerosis
HLA-DRB1*1501 Antigen presentation (81)
HLA-DRB1*0301
HLA-DQB1*0201
IL2RA = CD25 Mediation of IL-2 stimulation of T cells (81)
CD86 Role in costimulation, expressed on APCs (81)
TNFRSF1A Implication in TNF pathway (81)
TNFRSF14
TNFSF14
CYP27B1 Activation of vitamin D precursor (81)
Rheumatoid arthritis
HLA-DRB1*0401 Antigen presentation (170, 171, 
297–299)HLA-DRB1*0404
HLA-DRB1*0101
PTPN22 Down-regulation of T-cell activation (168, 300)
IL2RA = CD25 Mediation of IL-2 stimulation of T cells (168)
CTLA-4 Binds CD80 on APCs, inhibits T-cell 
activation
(168)
TNFAIP2 Implication in TNF pathway (168)
Type 1 diabetes
HLA-DQB1*0302 Antigen presentation (171, 301, 
302)HLA-DQ2
HLA-DRB1*0301
HLA-DRB1*0401
HLA-DRB1*0404
PTPN22 Down-regulation of T-cell activation (168, 303)
IL2RA = CD25 Mediation of IL-2 stimulation of T cells (168, 304)
CTLA-4 Binds CD80 on APCs, inhibits T-cell 
activation
(168, 305)
interferon-induced 
helicase 1 (IFIH1)
Pathogen recognition receptor for viral 
infection
(168, 306, 
307)
INS Codes for insulin (308)
Myasthenia gravis
HLA-B*08 Antigen presentation, association found in 
early-onset MG
(169)
PTPN22 Down-regulation of T-cell activation, 
association found in early-onset MG
(169)
TNIP1 (= TNFAIP3-
interacting protein)
Reduction of NFκB1 activation, 
association found in early-onset MG
(169)
Neuromyelitis optica
HLA-DPB1*0501 Antigen presentation, association in 
Asian, but not Caucasian NMO patients
(309, 310)
Autoimmune encephalitis
None reported so far
Some of the major disease susceptibility genes in MS, RA, T1D, MG, NMO, and AE 
reveal interesting similarities.
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far, most research has been done on myelin proteins, but there is 
evidence that also other antigens could serve as possible autoan-
tigens. In the following, some of the antigens derived from the 
myelin sheath are discussed in detail, which drew most attention 
of research in the past. Even though these are the most promising 
candidate autoantigens in MS, it will become clear that the data 
are not always consistent.
Myelin Basic Protein
Myelin basic protein is the second most abundant myelin protein 
after PLP. It is the only myelin component that can be found in 
both central and peripheral myelin. Thus, a peripheral activation of 
MBP-specific T cells seems more viable than of T cells reactive with 
other myelin components, from which they are normally separated.
It has been shown that there are MBP-reactive T cells in MS 
patients and healthy controls (19, 20). Several studies found 
significantly more IFN-γ-secreting T cells in response to differ-
ent MBP–peptides in MS patients than in controls, suggesting a 
quantitative increase of T cells exhibiting an activated phenotype 
(89, 174–176). Significantly more MBP-specific T-cell lines were 
found in the CSF of MS patients than of controls (23).
The central region of MBP84–102/MBP83–99, which can bind to 
several HLA-DRB molecules, was identified as immunodominant 
in several studies (177, 178). However, results varied with respect 
to differences in reactivities to MBP84–102 between MS patients and 
healthy controls. While some studies found increased reactivity to 
MBP84–102 in MS patients (20) or an enhanced response to MBP83–99 
in MS patients during relapse (87), others could not discover any 
discrepancies between the two cohorts (179–181). Krogsgaard 
et  al. showed by staining of CNS tissue of HLA-DR2-positive 
patients with a mAb specific for the HLA-DR2:MBP83–99 complex 
that this MBP epitope is locally presented in the CNS of MS 
patients, supporting a possible role as an autoantigen (182). Other 
epitopes described as immunodominant are MBP13–32 (177) and 
MBP144–163 (177)/MBP143–168 (23)/MBP151–170 (87). Interestingly, for 
high-affinity T cells, MBP83–99 was not immunodominant. Instead, 
MBP13–32, MBP111–129, and MBP146–170 were immunodominant in 
these T cells. Higher reactivities to these peptides were seen in 
MS patients (91).
After promising results in animal models, APLs based on 
the immunodominant epitope MBP83–99 were designed and 
administered in different phase II clinical trials. In one study, 
the APL successfully slightly reduced enhancing lesions at a 
certain dosage and skewed the T-cell response toward a Th2 
phenotype, so that the trial had to be stopped because of the 
occurrence of hypersensitivity reactions (183). However, in 
another study, the APL induced cross-recognition of MBP83–99 
and the APL by T cells in some patients, leading to exacerbation 
(84). One of the patients included in the latter study suffered 
two relapses under APL-treatment. Interestingly, before the first 
relapse, the number of T cells specific for MBP83–99 increased 
fivefold to decrease again after remission. In the second relapse, 
T cells specific for PLP190–209 were found expanded (80). This 
finding shows that myelin reactivity can correlate with disease 
progression and – besides other pieces of evidence – it also 
supports the notion of an immune pathogenesis of MS. In other 
studies, it could also be shown that T-cell reactivities against 
myelin components can correlate with disease progression, 
measured by using a disability score (174) or by assessment 
in MRI (176).
As MBP is an important candidate autoantigen in MS, its 
relationship with the disease-associated haplotype DR15 is of 
particular interest. Both HLA-DRB1*1501 and HLA-DRB5*0101 
contained in this haplotype can serve as restriction elements 
for MBP-reactive T cells (177). The immunodominant peptide 
MBP85–105, for example, seems to be able to be presented by 
both DRB1*1501 and DRB5*0101 (184, 185) and the complex 
DR2:MBP85–99 could be detected in tissue lesions (182).
TABLe 2 | Autoantigens in MS.
Autoantigen Remarks Reference
MBP T-cell responses and autoantibodies (91, 175, 311)
MOG T-cell responses and autoantibodies (193, 202)
PLP T-cell responses and autoantibodies (192, 311)
MAG T-cell responses and autoantibodies (312)
MOBP T-cell responses and autoantibodies (311, 313)
CNPase T-cell responses and autoantibodies (311, 314)
S100β T-cell responses (315)
Transaldolase T-cell responses and autoantibodies (316)
For overview of the autoantigens in MS discussed in this review, the respective antigens 
and the reactions they can evoke in MS patients are listed.
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A recent study showed that MBP is degraded by the 26S protea-
some without being ubiquitinated beforehand (186). Whether this 
discovery can be put in context with the pathogenesis of the disease 
remains to be resolved, but this shows very well how different 
aspects of antigen presentation might be involved in the emergence 
of autoimmune disease.
Proteolipid Protein
Proteolipid protein is the most abundant myelin protein. There are 
two isoforms: full-length PLP, which is nearly exclusively expressed 
in the CNS, and DM20, a splice variant of PLP missing a loop of 
25 amino acids, which is expressed in various peripheral organs 
like the thymus and lymph nodes (35). Only DM20 plays a role 
in negative selection in the thymus (27). The PLP loop contains 
the epitope PLP139–151, which seems predisposed to be a target of 
autoreactive T cells which can escape central tolerance induction 
in the thymus. However, enhanced reactivities to this epitope could 
only be detected in some studies (91), but not in others (181, 187).
T-cell responses to PLP seem to be heterogenous (188). 
Different epitopes have been identified as immunodominant in 
different studies (24, 180, 181, 187, 189, 190).
Some studies found higher proliferative responses (191) or 
higher precursor frequencies (23) of PLP-specific T-cell lines 
in MS patients. Higher reactivities to some PLP epitopes were 
detected in some studies in MS patients compared to controls (180, 
189). However, other studies could not detect any differences in 
reactivities against their epitopes detected as immunodominant 
between patients and controls (188, 190).
Myelin Oligodendrocyte glycoprotein
Myelin oligodendrocyte glycoprotein is a minor component of the 
myelin sheath. It could not be detected in the human thymus and 
might therefore evade presentation in central tolerance induction, 
supporting its possible role as an autoantigen (35). Many different 
studies have so far assessed T- and B-cell responses to this antigen.
Some studies have detected higher numbers of IFN-γ-
secreting cells (192, 193), higher numbers of T cells reactive 
with DRB1*0401/MOG97–109-tetramer (194), higher proliferative 
responses of peripheral blood lymphocytes (PBL) (195), or higher 
proliferative responses of T cells to certain MOG epitopes (196) 
in MS patients than in healthy controls.
Interestingly, there are also data that MOG could play a role 
in humoral autoimmunity in MS. MOG-specific autoantibodies 
have been discovered in acute lesions of MS patients (133, 134). 
Some studies also found higher levels of MOG-specific anti-
bodies or higher antibody responses to certain MOG epitopes 
in the serum of MS patients than in control sera (197–202) or 
in certain clinical subgroups of MS patients (203). However, 
other studies did not observe any differences between the sera 
of MS patients and healthy controls or patients with other 
neurological diseases, or did not detect any MOG-antibodies 
at all (134, 204, 205). The antibodies were shown to be actually 
demyelinating in an EAE experiment (200).
Data about a possible association of anti-MOG-antibodies (and 
anti-MBP-antibodies) with a progression from CIS to definite MS 
remain controversial (202, 206–210), rendering the use of these 
antibodies as biomarkers difficult.
There are interindividual differences concerning the specific 
MOG epitopes causing an antibody response (198, 211) and T-cell 
reactivities (212), which might also depend on the individual HLA 
type (213).
Important new data also indicate that MOG can interact 
with DC-specific intercellular adhesion molecule 3-grabbing 
non-integrin (DC-SIGN), which can induce IL-10 secretion 
and suppress T-cell proliferation. This interaction depends on 
the correct glycosylation state of MOG, which can be altered 
during inflammation (214). These findings could indicate that 
altered glycosylation of MOG can potentially result in disruption 
of tolerance and induction of anti-MOG-specific T- and B-cell 
responses.
Other and Novel Autoantigens in MS
Besides the above described antigens MBP, MOG, and PLP, 
myelin-associated antigen (MAG), myelin-associated oligo-
dendrocyte basic protein (MOBP), and 2′,3′-cyclic-nucleotide 
3′-phosphodiesterase (CNPase) have been shown to evoke T- or/
and B-cell responses in patients with MS. Apart from these myelin 
components, other antigens like S100β protein or transaldolase 
H are discussed as autoantigens in MS (56). While a-B-crystallin 
was first thought to be an autoantigen in MS (215), more recent 
data indicate that it serves as a chaperone and does not fulfill the 
criteria of an autoantigen (216). In another study, 300 peptides 
presented on MHC class I and MHC class II molecules in the 
CNS of MS patients were eluted and identified. Among them, 
widely investigated proteins like MBP were found, but also non-
myelin proteins could be detected (217). Table  2 summarizes 
the autoantigens discussed in MS. For a comparison with other 
autoimmune diseases, Tables 3 and 4 summarize some important 
candidate autoantigens in MG, NMO, T1D, RA, and AE.
Autoantigens in Other Autoimmune 
Diseases
Myasthenia gravis
Myasthenia gravis is a neurological disease characterized by muscle 
weakness which worsens by exertion and improves by rest (218).
Some decades ago, antibodies directed against nicotine 
acetylcholine receptors (nAChR) were detected in most MG 
patients (219, 220), which could also be shown to be pathogenic 
by a transfer of sera to mice (221). A considerable part of the 
TABLe 3 | Autoantigens in other (peripheral) autoimmune diseases.
Autoantigen Remarks Reference
Myasthenia gravis
nAChR Antibodies in most MG patients (223)
MuSK Antibodies in “seronegative” MG patients (222)
LRP4 Antibodies in “seronegative” MG patients (224, 317)
Diabetes mellitus type 1
Insulin Antibodies already in prediabetics (253, 254)
T-cell reactivities to different epitopes
IA-2 Antibodies in 50% of diabetics (257, 259)
T-cell responses in context of HLA-DR4
GAD-65 Antibodies in >80% of diabetics (256, 
260–262)Elevated T-cell responses
ZnT8 Antibodies in 60–80% of diabetics at onset 
of disease
(258, 263)
Elevated T-cell responses
IGRP Elevated T-cell responses (264)
Chromogranin A Elevated T-cell responses (265)
Rheumatoid arthritis
Fc-part of 
immunoglobulins
Antibodies in >80% of RA patients 
(rheumatoid factor)
(277)
Citrullinated antigens Antibodies before and during disease 
course
(281, 282)
Specific B cells in synovial fluid
Carbamylated 
antigens
Antibodies in 45% of RA patients (286)
Collagen Antibodies to post-translationally modified 
forms
(287, 288)
Antibodies to denatured forms
65-kDa heat-shock 
protein
Antibodies in RA patients (279)
Cartilage 
glycoprotein-39
T-cell responses in RA patients (275)
Aggrecan G1 T-cell responses in RA patients (276)
Important (candidate) autoantigens of MG, T1D, and RA are shown. It can be 
comprehended that in T1D and RA, there are several candidate autoantigens evoking 
B- and/or T-cell responses, whereas in MG, the target antigens are already more clear.
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10–20% of MG patients who had long been assessed as seron-
egative for nAChR-autoantibodies could be shown to possess 
autoantibodies against the receptor tyrosine kinase MuSK (222) 
or still possess low-affinity antibodies against the nAChR by 
employing a more sensitive assay (223). More recently, also 
low-density lipoprotein receptor-related protein (Lrp4) was 
identified to be a target of autoantibodies in a small proportion 
of seronegative MG patients (224). These findings point toward 
B cells playing the central role in the pathogenesis of MG. But 
also nAChR-specific T lymphocytes have been discovered (22, 
225), consistent with necessary T cell help and activation for an 
autoantibody production by B cells. Regulatory T cells isolated 
from thymi of MG patients showed a reduced suppressive 
capability (226).
Even though B cells and their antibodies seem to play a crucial 
role for the disease, its exact pathogenesis could not be revealed 
yet. Complement activation by autoantibodies and crosslinking 
nAChR leading to their degradation were suggested to be under-
lying pathogenic mechanisms of the nAChR-autoantibodies 
(218). But still, the emergence of an autoimmune disease always 
requires an interplay of different immune cell types and T cells 
are probable to play an important role. Like in MS, as discussed 
TABLe 4 | Autoantigens in NMO and autoimmune encephalitides as 
examples of other CNS autoimmune diseases.
Autoantigen Remarks Reference
Neuromyelitis optica
AQP-4 Antibodies in 73% of NMO patients (229)
MOG Antibodies in 7% of NMO-spectrum disorder 
patients
(238)
Autoimmune encephalitides to membrane antigens
NMDA-receptor Antibodies in patients with limbic 
encephalitis, psychotic behavior
(289, 291)
AMPA-receptor Antibodies in patients with limbic 
encephalitis
(289)
GABAA-receptor Antibodies in patients with anti-GABA-A 
receptor encephalitis
(318)
GABAB-receptor Antibodies in patients with limbic 
encephalitis
(289)
Gly-receptor Antibodies in patients with limbic 
encephalitis, Stiff person syndrome
(289)
DPPX Antibodies in patients with anti-DPPX-
associated encephalitis
(319)
GluR5 Antibodies in patients with anti-GluR5 
encephalitis
(320)
VGKC-complex Antibodies in patients with limbic 
encephalitis, faciobrachial dystonic seizures, 
Morvan’s syndrome, neuromyotonia
(289)
Autoimmune encephalitides to intracellular antigens
Hu T cells and antibodies in patients with  
anti-Hu encephalitis
(321, 322)
Jo (323, 324), Ri (325), Ma1 (326), Ma2 (327), Zic4 (328), GAD-65 (329), 
CRMP5 (330), and amphiphysin (331) as target of autoantibodies in patients 
with the respective encephalitis forms
above, it could also be shown that B cells can serve as APCs in 
MG (227).
Compared to MS, the autoimmune origin of the disease is 
evidenced very clearly and the nAChR is well characterized as 
the target structure of the autoimmune response. But still, the 
exact etiology of the disease remains to be clarified.
Neuromyelitis Optica
Neuromyelitis optica is a demyelinating disease of the CNS 
characterized by optic neuritis and longitudinally extensive 
transverse myelitis (228). Originally, the disease was not differ-
entiated from MS, but important differences between NMO and 
MS will be pointed out in the following. Autoantibodies directed 
against aquaporin-4 (AQP-4)-channels were discovered in 73% 
of sera of NMO patients but not in sera of MS patients (229, 
230). Anti-AQP-4 antibodies also seem to have some predictive 
value concerning the clinical course of the disease (231). AQP-
4-channels are expressed on astrocytic foot processes at the BBB 
(230, 232). Pathological findings indicate a complete loss of AQP-4 
in NMO lesions, whereas in MS, AQP-4 staining was enhanced in 
the periplaque white matter of active lesions, and absent in inactive 
lesions (232). There is evidence that these antibodies might also be 
pathogenic. They were found to have cytotoxic effects on astrocytes 
in the presence of complement (233, 234), increase natural killer 
cell-mediated cytotoxicity (235, 236), complement-mediated 
involvement of granulocytes (235, 236), and the permeability of 
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the BBB (235). In animal studies, a more severe disease course of 
EAE displaying features of NMO was observed (236, 237).
There are also NMO patients who are seronegative for AQP-
4-antibodies. In 7% of patients with NMO-spectrum disorders 
(NMOSD), i.e., patients presenting either with isolated transverse 
myelitis or optic neuritis, MOG-antibodies were discovered (238). 
Also AQP-4-antibody-negative patients with classical signs of 
NMO have been described to possess antibodies to MOG (239). 
However, MOG-antibodies seem to be less specific for NMO. 
MOG-antibody-positive patients with NMOSD also seem to show 
a milder clinical course than AQP-4-positive patients (238). Data 
in animal models of NMO indicate that the T-cell response is not 
mandatory for the development of NMO if AQP-4 antibodies are 
present in serum or CSF. The access of the antibodies to the CNS 
and their binding to astrocytes appears to be most important (240, 
241). Consistent with an important role of a loss of B-cell tolerance, 
regulatory B cells were found decreased in NMO and secreted less 
IL-10 (97). Nevertheless, T cells seem to be mandatory for the 
initial emergence of plasma cells which secrete AQP-4-specific 
antibodies (242, 243).
So even though NMO can sometimes clinically resemble MS, 
the mechanisms of their pathogeneses seem to differ greatly in 
regard to the autoimmune target and the emerging immune 
response.
Type 1 Diabetes
Type 1 diabetes is an autoimmune disease in which the β-cells in 
the Langerhans islands of the pancreas are destroyed, resulting 
in a lack of insulin. It is thought that T cells play a more decisive 
role in β-cell destruction than B cells, but B cells were shown to 
be relevant by producing autoantibodies against islet cell antigens 
already in prediabetic phases and by presenting antigen to CD4+ 
and CD8+ T cells (244). Concerning CD4+ T cells, Th1 and Th17 
cells seem to be the most significant T helper cell subsets for T1D. 
The animal model of T1D is mainly driven by Th1 cells, but there 
is also evidence of a role of Th1 cells in human T1D (245). More 
IL-17-secreting T cells were detected in recent-onset T1D and 
IL-17 seems to promote the inflammatory response to β-cells 
(246, 247). Th17 cells were also found increased in pancreatic-
draining lymph nodes (248). Insulin-specific CD8+ T cells could 
be associated with an autoimmune destruction of transplanted 
Langerhans islands (249). CD8+ T cells were also more frequent in 
pancreatic-draining lymph nodes than in those of controls (248). 
Similar to MS, defects in the suppressive capabilities of regulatory 
T cells have been detected (250). This was also shown for T cells 
residing in pancreatic-draining lymph nodes (248). On the other 
hand, also a higher resistance of effector T cells to suppression 
by regulatory T cells has been reported (251). Possible defects in 
central and peripheral B-cell tolerance were also reported (141). 
Epitope spreading also seems to be an important mechanism in the 
autoimmune response in T1D, intermolecular epitope spreading 
was observed even before the clinical onset of the disease (252).
Different antigens are discussed as autoantigens in T1D. Among 
them, insulin seems to play a major role: in some diabetics, anti-
bodies to insulin can be discovered before insulin treatment (253). 
Most T1D patients were shown to possess CD8+ T cells reactive 
with proinsulin peptides (254).
Islet cell autoantibodies (ICA) were detected to be more fre-
quent in T1D patients and were also suggested to have predictive 
value (255). Many T1D patients also exhibit antibodies against 
the enzyme glutamic acid decarboxylase (GAD)-65, which is 
expressed in neurons and in pancreatic β-cells (256). Subsequently, 
also autoantibodies against tyrosine phosphatase-like islet-antigen 
2 (IA-2) (257) and against the zinc transporter ZnT8 (258) were 
detected in diabetics.
In addition to insulin, T-cell reactivities against several other 
antigens were identified: not only autoantibodies, but also T-cell 
responses against IA-2 and GAD-65 were detected, especially in the 
context of HLA-DR4 (259–262). Also ZnT8 seems to evoke elevated 
T-cell responses in diabetics (263). Human PBMCs of patients with 
recent-onset diabetes also showed elevated IFN-γ secretion when 
stimulated with islet-specific glucose-6-phosphatase catalytic 
subunit-related protein (IGRP), supporting a possible role as an 
autoantigen (264). Chromogranin A was also discovered to be a 
relevant T-cell antigen in human T1D (265).
On the whole, there are several features MS and T1D have 
in common. Their animal models seem to be mainly driven by 
autoreactive Th1 cells, but both animal and human data indicate 
also an important role of Th17 cells and an impaired function 
of regulatory populations. Their major genetic risk loci code for 
MHC molecules and several T- and B-cell antigens have been 
suggested as putative target structures. Interestingly, T1D has also 
been reported to display cyclic processes in the ongoing β-cell 
destruction, characterized by damage by autoreactive T cells, 
epitope spreading, β-cell proliferation, and suppressive activities by 
regulatory T cells (266). This could resemble a relapsing-remitting 
course as found in most MS patients.
Rheumatoid Arthritis
In RA, it is not fully resolved whether T cells or B cells play the 
more important role in its pathogenesis, for there are important 
aspects supporting a relevance of both cell types. T- and B-cell 
clones have been detected in the joints of RA patients, partly 
even the same clones were found in different affected joints 
(267, 268). Like in MS and T1D, a pathogenic role of Th1 and 
Th17 cells has been suggested. Th1 cells were encountered much 
more frequently than Th17 cells in the joint of RA patients with 
established disease (269). On the other hand, increased numbers 
of Th17 cells and higher IL-17 levels were found in peripheral 
blood and synovial fluid of patients with untreated early RA 
(270). Part of their pathogenicity might be due to the effect 
of IL-17, which among other cytokines leads to an increased 
production of TNF-α (271), which plays a pivotal role in the 
pathogenesis of RA. Th17 memory cells can also induce secre-
tion of proinflammatory cytokines by synovial fibroblasts (272). 
Regulatory T cells in RA have been found less able to suppress 
the production of proinflammatory cytokines like TNFα in 
acute phases of the disease (273). B cells do not only secrete 
potentially pathogenic antibodies, but also their function in 
cellular immunity plays a role in RA, as T cells were shown to be 
activated by B cells in synovitis (267). Defects in both peripheral 
and central B-cell tolerance were observed (141). The efficacy 
of a treatment with rituximab confirms a pathogenic role of B 
cells in the disease (274).
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Like in MS and T1D, several different antigens are discussed 
as autoantigens in RA; some of the possible targets in RA will be 
discussed here.
Examples for putative T-cell targets in RA include the human 
cartilage glycoprotein-39 (275) and aggrecan G1 (276). Some 
autoantibodies target the Fc-part of immunoglobulins (277). 
These antibodies are also referred to as the “rheumatoid factor.” The 
presence of the rheumatoid factor is associated with a more severe 
disease course (278). Elevated autoantibodies against 65-kDa heat-
shock protein have also been detected in RA patients compared to 
controls (279). An interesting aspect of the autoimmune response 
in RA is that it also seems to be directed against post-translational 
modifications of antigens like citrullination or carbamylation 
(280). Antibodies against different citrullinated antigens are found 
significantly more often in RA patients compared to controls and 
are elevated already before the onset of disease (281). A considerable 
proportion of B cells found in synovial fluid have been observed 
to secrete antibodies directed against citrullinated antigens (282). 
Epitope spreading of the antibody response to different citrullinated 
peptides has been observed even before the clinical onset of RA 
(283). Data from animal models indicate that antibodies directed 
against citrullinated antigens are pathogenic and worsen arthritis 
(284). Human data indicate that anti-cyclic citrullinated antibod-
ies can lead to complement activation (285). Independently from 
APCA, antibodies directed against carbamylated antigens have been 
discovered in about 45% of RA patients (286). In early stages of RA, 
autoantibodies against post-translationally modified collagen have 
recently been detected in over 90% or RA patients (287). During 
the course of the disease, also higher antibody titers to denaturated 
collagen were found in RA patients than in controls (288).
Like T1D and MS, also RA shows an HLA-association, an 
important role of Th1 and Th17 cells and possible defects in 
regulatory mechanisms. In contrast to MS and T1D, autoimmune 
responses to post-translational modifications have been studied 
more extensively in RA.
Autoimmune encephalitides
In the last years, several antibody-mediated AE were discovered 
with immune responses to membrane-bound proteins, which 
respond well to immunotherapies like plasmapheresis. Symptoms 
range from psychiatric symptoms, such as personality and behavio-
ral change, agitation and paranoia, to epilepsy, amnesia, and many 
others. Antibodies against different neuronal antigens were found 
in different disorders, with most autoantigens directed against cer-
tain ion channel proteins or receptors involved in brain signaling. 
For example, antibodies against N-methyl-D-aspartate (NMDA) 
receptors, alpha-amino-3-hydroxy-5-methyl-4-isoxazoleprionic 
acid (AMPA)-receptors, gamma-aminobutyric acid (GABA) type 
A or B receptors, glycine receptors (GlyR), dipeptidyl-peptidase-
like-protein 6 (DPPX), metabotrophic glutamate receptor 5 
(GluR5), or voltage-gated potassium channels were detected in 
patients with different forms of autoimmune encephalitis (289).
As an example, only anti-NMDA-receptor encephalitis is briefly 
discussed here, as there is evidence of a direct pathogenic relevance 
of the autoantibodies by leading to receptor internalization (290). 
The occurring autoantibodies were detected to be directed against 
heteromers of the NMDA-receptor containing the subunits NR2B 
or NR2A (291). A pathological study barely found markers of 
cell cytotoxicity, but large deposits of IgG, pointing toward a 
functionally primary causative role of antibodies produced by B 
cells instead of cellular immunity (292). Anti-NMDA-receptor 
encephalitis as well as other types of autoimmune encephalitis can 
be of paraneoplastic origin. Associations of anti-NMDA-receptor 
encephalitis with ovarian teratoma have been described (291). The 
role of T cells in these encephalitis forms is not well established 
yet. Possibly they are instrumental for disease initiation by helping 
B cells to secrete pathogenic antibodies.
There are many intracellularly located target antigens that can 
cause autoimmune encephalitis. Many of these are induced by 
paraneoplastic mechanisms, but there are also pure autoimmune 
conditions. Most probably, T cells and especially CD8+ T cells 
are of paramount importance by leading to tissue damage (293, 
294). For diagnoses, antibodies against such antigens are pivotal. 
Antigens that have been described as target antigens and to which 
also antibodies are found in patients are Hu, Yo, Ri, Ma1, Ma2, 
Zic4, GAD-65, CRMP5, and amphiphysin (Table 4).
ways to the Autoantigens
Principally, possible autoantigens can be determined by testing the 
immune reaction against antigens that can be assumed to be tar-
geted in an autoimmune disease because of certain characteristics 
of the disease (e.g., myelin antigens in the demyelinating disease 
MS). As described above, there has already been much research 
investigating the role of myelin antigens in MS.
Another way to determine possible autoantigens would be 
first to identify possible candidate autoantigens of the disease, 
e.g., by elution of peptides presented on MHC molecules of 
APCs in affected individuals or by screening sera of patients for 
autoantibodies, and afterwards test the actual functional role of 
the findings. The approach to elute peptides presented on APCs in 
autoimmunity has been successfully applied in research on differ-
ent autoimmune diseases like RA or T1D (173, 259, 260, 295), but 
also in MS (217). The eluted peptides from the CNS of MS patients 
might have a high potential as autoantigens, since antigen presenta-
tion in the healthy CNS is low. In active MS lesions, however, MHC 
molecules have been observed to be upregulated (82).
Conclusion
In all autoimmune diseases, the importance of the role of pep-
tide–MHC–TCR interactions cannot be underestimated. Antigen 
presentation is in the center of every autoimmune disease, influ-
encing both tolerance induction in the thymus and self-antigen 
recognition and immune cell activation in the periphery. This 
is underlined by the fact that the genetic risk factors of many 
autoimmune diseases are conferred by genes involved in antigen 
presentation. The onset of several physiological immune mecha-
nisms like epitope spreading obscures the search for the primary 
underlying target of the ongoing immune attack. This underlines 
the great importance of studying immune reactions in recently 
diagnosed patients or even before diagnosis for eventually being 
able to determine the primary event in MS and other diseases of a 
putative autoimmune origin. On the other hand, for more efficient 
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therapy development, the processes which set in later during the 
course of an autoimmune disease must be taken into account as 
well. In the discussed autoimmune diseases, the emergence of 
neo-antigens by tissue destruction and epitope spreading play a 
role. To give only one example, this might be a reason for the 
failure of therapeutic trials with peptides based only on MBP in 
MS treatment. Recently, evidence was adduced that the native con-
formation of an antigen is of importance for inducing an immune 
response (296). This is of great relevance for studies investigating 
possible autoantigens, since antigens are not always employed in 
their native conformation; which further complicates the search 
for the principal autoantigen(s).
It is striking that many susceptibility genes conferring risk 
for different autoimmune diseases code for HLA genes, further 
emphasizing the extreme relevance of antigen presentation for 
autoimmune diseases. A comparison of MS with other autoim-
mune diseases is interesting also in other respects: the exact 
pathogenesis has not been identified yet in either autoimmune 
disease. The determination of the (primary) autoantigens is a 
crucial step in understanding the pathogenesis of a disease. 
But even when target antigens have been identified like in MG 
or NMO, the pathogenic mechanism can still remain unclear. 
Neither has it been resolved which cell types play the dominant 
role in the induction of an autoimmune disease. The concept 
of MS being a “T-cell-mediated” autoimmune disease and MG 
being a “B-cell-mediated” autoimmune disease must be reevalu-
ated. Data indicate that autoimmune diseases emerge from a 
complex interplay of many different factors of the immune 
system.
Comparisons of MS with RA or T1D show that there are more 
diseases whose target antigen(s) have not been fully identified. 
Until an unequivocal target of the immune attack has been identi-
fied in MS and other diseases, there will also remain the question 
if the causative factors might even be heterogenic.
At all events, a detailed understanding of the etiology of the 
discussed autoimmune diseases is an enormous challenge, but will 
remain a prerequisite for the development of new, specific, and 
more efficient treatment options.
Author Contributions
CR and RW outlined the subject of the review, searched for, 
analyzed, and interpreted the literature and wrote the manuscript. 
CR and RW agree to be accountable for all aspects of the work.
References
 1. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: 
an overview. Brain Pathol (2007) 17:210–8. doi:10.1111/j.1750-3639.2007.00064.x 
 2. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev 
Immunol (2013) 31:443–73. doi:10.1146/annurev-immunol-032712-095910 
 3. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al.  Inhibitors of 
the proteasome block the degradation of most cell proteins and the generation 
of peptides presented on MHC class I molecules. Cell (1994) 78:761–71. 
doi:10.1016/S0092-8674(94)90462-6 
 4. Gaczynska M, Rock KL, Spies T, Goldberg AL. Peptidase activities of proteasomes 
are differentially regulated by the major histocompatibility complex-encoded 
genes for LMP2 and LMP7. Proc Natl Acad Sci U S A (1994) 91:9213–7. 
doi:10.1073/pnas.91.20.9213 
 5. Saric T, Chang S, Hattori A, York IA, Markant S, Rock KL, et al.  An IFN-gamma-
induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class 
I-presented peptides. Nat Immunol (2002) 3:1169–76. doi:10.1038/ni859 
 6. York IA, Chang S, Saric T, Keys JA, Favreau JM, Goldberg AL, et al.  The ER 
aminopeptidase ERAP1 enhances or limits antigen presentation by trimming 
epitopes to 8-9 residues. Nat Immunol (2002) 3:1177–84. doi:10.1038/ni860 
 7. Sadasivan B, Lehner PJ, Ortmann B, Spies T, Cresswell P. Roles for calreticulin 
and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules 
with TAP. Immunity (1996) 5:103–14. doi:10.1016/S1074-7613(00)80487-2 
 8. Momburg F, Roelse J, Howard JC, Butcher GW, Hämmerling GJ, Neefjes JJ. 
Selectivity of MHC-encoded peptide transporters from human, mouse and rat. 
Nature (1994) 367:648–51. doi:10.1038/367648a0 
 9. Watts C. The exogenous pathway for antigen presentation on major histocom-
patibility complex class II and CD1 molecules. Nat Immunol (2004) 5:685–92. 
doi:10.1038/ni1088 
 10. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. HLA-DR 
molecules from an antigen-processing mutant cell line are associated with 
invariant chain peptides. Nature (1992) 360:474–7. doi:10.1038/360474a0 
 11. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class 
II alpha beta dimers and facilitates peptide loading. Cell (1995) 82:155–65. 
doi:10.1016/0092-8674(95)90061-6 
 12. Ford AL, Foulcher E, Lemckert FA, Sedgwick JD. Microglia induce CD4 T 
lymphocyte final effector function and death. J Exp Med (1996) 184:1737–45. 
doi:10.1084/jem.184.5.1737 
 13. Fontana A, Fierz W, Wekerle H. Astrocytes present myelin basic protein to 
encephalitogenic T-cell lines. Nature (1984) 307:273–6. doi:10.1038/307273a0 
 14. Gresser O, Weber E, Hellwig A, Riese S, Régnier-Vigouroux A. Immuno- 
competent astrocytes and microglia display major differences in the 
processing of the invariant chain and in the expression of active cathep-
sin L and cathepsin S. Eur J Immunol (2001) 31:1813–24. doi:10.1002/ 
1521-4141(200106)31:6<1813::AID-IMMU1813>3.0.CO;2-8 
 15. Ackerman AL, Giodini A, Cresswell P. A role for the endoplasmic reticulum 
protein retrotranslocation machinery during crosspresentation by dendritic 
cells. Immunity (2006) 25:607–17. doi:10.1016/j.immuni.2006.08.017 
 16. Malnati MS, Marti M, LaVaute T, Jaraquemada D, Biddison W, DeMars R, 
et al.  Processing pathways for presentation of cytosolic antigen to MHC class 
II-restricted T cells. Nature (1992) 357:702–4. doi:10.1038/357702a0 
 17. Saveanu L, Carroll O, Weimershaus M, Guermonprez P, Firat E, Lindo V, 
et al.  IRAP identifies an endosomal compartment required for MHC class I 
cross-presentation. Science (2009) 325:213–7. doi:10.1126/science.1172845 
 18. Segura E, Albiston AL, Wicks IP, Chai SY, Villadangos JA. Different cross-pre-
sentation pathways in steady-state and inflammatory dendritic cells. Proc Natl 
Acad Sci U S A (2009) 106:20377–81. doi:10.1073/pnas.0910295106 
 19. Martin R, Jaraquemada D, Flerlage M, Richert J, Whitaker J, Long EO, et al. 
Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic 
T cell lines from multiple sclerosis patients and healthy individuals. J Immunol 
(1990) 145:540–8. 
 20. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell 
recognition of an immunodominant myelin basic protein epitope in multiple 
sclerosis. Nature (1990) 346:183–7. doi:10.1038/346183a0 
 21. Burns JB, Bartholomew BD, Lobo ST. Isolation of CD45RO+, memory T cells 
recognizing proteolipid protein from neurologically normal subjects. Cell 
Immunol (2001) 212:44–50. doi:10.1006/cimm.2001.1842 
 22. Melms A, Malcherek G, Gern U, Wiethölter H, Müller CA, Schoepfer R, et al.  T 
cells from normal and myasthenic individuals recognize the human acetylcholine 
receptor: heterogeneity of antigenic sites on the alpha-subunit. Ann Neurol (1992) 
31:311–8. doi:10.1002/ana.410310314 
 23. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased 
frequency of interleukin 2-responsive T cells specific for myelin basic pro-
tein and proteolipid protein in peripheral blood and cerebrospinal fluid of 
patients with multiple sclerosis. J Exp Med (1994) 179:973–84. doi:10.1084/
jem.179.3.973 
June 2015 | Volume 6 | Article 32215
Riedhammer and Weissert Antigen presentation in multiple sclerosis
Frontiers in Immunology | www.frontiersin.org
 24. Correale J, McMillan M, McCarthy K, Le T, Weiner LP. Isolation and char-
acterization of autoreactive proteolipid protein-peptide specific T-cell clones 
from multiple sclerosis patients. Neurology (1995) 45:1370–8. doi:10.1212/
WNL.45.7.1370 
 25. Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R. 
Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and 
healthy subjects: epitope spreading versus clonal persistence. Brain (2000) 
123:508–18. doi:10.1093/brain/123.3.508 
 26. Tsuchida T, Parker KC, Turner RV, McFarland HF, Coligan JE, Biddison WE. 
Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides. 
Proc Natl Acad Sci U S A (1994) 91:10859–63. doi:10.1073/pnas.91.23.10859 
 27. Klein L, Klugmann M, Nave KA, Tuohy VK, Kyewski B. Shaping of the auto-
reactive T-cell repertoire by a splice variant of self protein expressed in thymic 
epithelial cells. Nat Med (2000) 6:56–61. doi:10.1038/71540 
 28. Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the 
thymus for positive selection and central tolerance induction. Nat Rev Immunol 
(2009) 9:833–44. doi:10.1038/nri2669 
 29. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, et al.  Projection 
of an immunological self shadow within the thymus by the aire protein. Science 
(2002) 298:1395–401. doi:10.1126/science.1075958 
 30. García-Lozano J, Torres-Agrela B, Montes-Cano M, Ortiz-Fernández L, Conde-
Jaldón M, Teruel M, et al.  Association of the AIRE gene with susceptibility to 
rheumatoid arthritis in a European population: a case control study. Arthritis 
Res Ther (2013) 15:R11. doi:10.1186/ar4141 
 31. Shao S, Li X, Cen H, Yin Z. Association of AIRE polymorphisms with genetic 
susceptibility to rheumatoid arthritis in a Chinese population. Inflammation 
(2014) 37:495–9. doi:10.1007/s10753-013-9763-3 
 32. Giraud M, Taubert R, Vandiedonck C, Ke X, Lévi-Strauss M, Pagani F, et al. 
An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous 
expression in thymus. Nature (2007) 448:934–7. doi:10.1038/nature06066 
 33. Wu C, Aichinger M, Nedjic J, Klein L. Thymic epithelial cells use macroautophagy 
to turn their inside out for CD4 T cell tolerance. Autophagy (2013) 9:931–2. 
doi:10.4161/auto.24374 
 34. Adamopoulou E, Tenzer S, Hillen N, Klug P, Rota IA, Tietz S, et al.  Exploring the 
MHC-peptide matrix of central tolerance in the human thymus. Nat Commun 
(2013) 4:2039. doi:10.1038/ncomms3039 
 35. Bruno R, Sabater L, Sospedra M, Ferrer-Francesch X, Escudero D, Martínez-Cáceres 
E, et al.  Multiple sclerosis candidate autoantigens except myelin oligodendrocyte 
glycoprotein are transcribed in human thymus. Eur J Immunol (2002) 32:2737–47. 
doi:10.1002/1521-4141(2002010)32:10<2737::AID-IMMU2737>3.0.CO;2-0 
 36. Pribyl TM, Campagnoni CW, Kampf K, Kashima T, Handley VW, McMahon J, 
et al.  The human myelin basic protein gene is included within a 179-kilobase 
transcription unit: expression in the immune and central nervous systems. Proc 
Natl Acad Sci U S A (1993) 90:10695–9. doi:10.1073/pnas.90.22.10695 
 37. Goverman J. Autoimmune T cell responses in the central nervous system. Nat 
Rev Immunol (2009) 9:393–407. doi:10.1038/nri2550 
 38. Greer JM, Denis B, Sobel RA, Trifilieff E. Thiopalmitoylation of myelin proteolipid 
protein epitopes enhances immunogenicity and encephalitogenicity. J Immunol 
(2001) 166:6907–13. doi:10.4049/jimmunol.166.11.6907 
 39. Bradford CM, Ramos I, Cross AK, Haddock G, McQuaid S, Nicholas AP, et al. 
Localisation of citrullinated proteins in normal appearing white matter and 
lesions in the central nervous system in multiple sclerosis. J Neuroimmunol (2014) 
273:85–95. doi:10.1016/j.jneuroim.2014.05.007 
 40. Sethi DK, Schubert DA, Anders A, Heroux A, Bonsor DA, Thomas CP, et al. 
A highly tilted binding mode by a self-reactive T cell receptor results in altered 
engagement of peptide and MHC. J Exp Med (2011) 208:91–102. doi:10.1084/
jem.20100725 
 41. Schubert DA, Gordo S, Sabatino JJ, Vardhana S, Gagnon E, Sethi DK, et al. 
Self-reactive human CD4 T cell clones form unusual immunological synapses. 
J Exp Med (2012) 209:335–52. doi:10.1084/jem.20111485 
 42. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med (2001) 
344:655–64. doi:10.1056/NEJM200103013440907 
 43. Liu J, Zhang H. CTLA-4 gene and the susceptibility of multiple sclerosis: an 
updated meta-analysis study including 12,916 cases and 15,455 controls. 
J Neurogenet (2014) 28:153–63. doi:10.3109/01677063.2014.880703 
 44. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased 
dependence of myelin basic protein-reactive T cells on CD28-mediated costim-
ulation in multiple sclerosis patients. A marker of activated/memory T cells. 
J Clin Invest (1998) 101:725–30. doi:10.1172/JCI1528 
 45. Scholz C, Patton KT, Anderson DE, Freeman GJ, Hafler DA. Expansion of autore-
active T cells in multiple sclerosis is independent of exogenous B7 costimulation. 
J Immunol (1998) 160:1532–8. 
 46. Oliveira EM, Bar-Or A, Waliszewska AI, Cai G, Anderson DE, Krieger JI, 
et al.  CTLA-4 dysregulation in the activation of myelin basic protein reactive 
T cells may distinguish patients with multiple sclerosis from healthy controls. J 
Autoimmun (2003) 20:71–81. doi:10.1016/S0896-8411(02)00106-3 
 47. Markovic-Plese S, Cortese I, Wandinger KP, McFarland HF, Martin R. 
CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin 
Invest (2001) 108:1185–94. doi:10.1172/JCI12516 
 48. Genç K, Dona DL, Reder AT. Increased CD80(+) B cells in active multiple scle-
rosis and reversal by interferon beta-1b therapy. J Clin Invest (1997) 99:2664–71. 
doi:10.1172/JCI119455 
 49. Moreno M, Negrotto L, Río J, Moubarak R, Martín I, Bustamante MF, et al. 
Activation-induced cell death in T lymphocytes from multiple sclerosis patients. 
J Neuroimmunol (2014) 272:51–5. doi:10.1016/j.jneuroim.2014.04.007 
 50. Macchi B, Matteucci C, Nocentini U, Caltagirone C, Mastino A. Impaired 
apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis. 
Neuroreport (1999) 10:399–402. doi:10.1097/00001756-199902050-00034 
 51. Cencioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG, et al. 
FAS-ligand regulates differential activation-induced cell death of human T-helper 
1 and 17 cells in healthy donors and multiple sclerosis patients. Cell Death Dis 
(2015) 6:e1741. doi:10.1038/cddis.2015.100 
 52. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and 
function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 4:330–6. 
doi:10.1038/ni904 
 53. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. 
Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. 
Immunity (2005) 22:329–41. doi:10.1016/j.immuni.2005.01.016 
 54. Aschenbrenner K, D’Cruz LM, Vollmann EH, Hinterberger M, Emmerich J, 
Swee LK, et al.  Selection of Foxp3+ regulatory T cells specific for self antigen 
expressed and presented by Aire+ medullary thymic epithelial cells. Nat Immunol 
(2007) 8:351–8. doi:10.1038/ni1444 
 55. Kivisäkk P, Mahad DJ, Callahan MK, Trebst C, Tucky B, Wei T, et al.  Human 
cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking 
through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A 
(2003) 100:8389–94. doi:10.1073/pnas.1433000100 
 56. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 
(2005) 23:683–747. doi:10.1146/annurev.immunol.23.021704.115707 
 57. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science (1996) 
272:60–6. doi:10.1126/science.272.5258.60 
 58. Ransohoff RM, Kivisäkk P, Kidd G. Three or more routes for leukocyte migration 
into the central nervous system. Nat Rev Immunol (2003) 3:569–81. doi:10.1038/
nri1130 
 59. de Vos AF, van Meurs M, Brok HP, Boven LA, Hintzen RQ, van der Valk P, 
et al.  Transfer of central nervous system autoantigens and presentation in 
secondary lymphoid organs. J Immunol (2002) 169:5415–23. doi:10.4049/
jimmunol.169.10.5415 
 60. Fabriek BO, Zwemmer JN, Teunissen CE, Dijkstra CD, Polman CH, Laman JD, 
et al.  In vivo detection of myelin proteins in cervical lymph nodes of MS patients 
using ultrasound-guided fine-needle aspiration cytology. J Neuroimmunol (2005) 
161:190–4. doi:10.1016/j.jneuroim.2004.12.018 
 61. Waldner H, Collins M, Kuchroo VK. Activation of antigen-presenting cells by 
microbial products breaks self tolerance and induces autoimmune disease. J Clin 
Invest (2004) 113:990–7. doi:10.1172/JCI19388 
 62. Birnbaum ME, Mendoza JL, Sethi DK, Dong S, Glanville J, Dobbins J, et al. 
Deconstructing the peptide-MHC specificity of T cell recognition. Cell (2014) 
157:1073–87. doi:10.1016/j.cell.2014.03.047 
 63. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated 
autoimmunity: viral peptides activate human T cell clones specific for myelin 
basic protein. Cell (1995) 80:695–705. doi:10.1016/0092-8674(95)90348-8 
 64. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ. Cross-reactivity 
with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann 
Neurol (2003) 53:189–97. doi:10.1002/ana.10425 
 65. Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernán MA, Olek MJ, 
et al.  Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective 
study. JAMA (2001) 286:3083–8. doi:10.1001/jama.286.24.3083 
 66. Croxford JL, Olson JK, Anger HA, Miller SD. Initiation and exacerbation of 
autoimmune demyelination of the central nervous system via virus-induced 
June 2015 | Volume 6 | Article 32216
Riedhammer and Weissert Antigen presentation in multiple sclerosis
Frontiers in Immunology | www.frontiersin.org
molecular mimicry: implications for the pathogenesis of multiple sclerosis. J 
Virol (2005) 79:8581–90. doi:10.1128/JVI.79.13.8581-8590.2005 
 67. Krishnamoorthy G, Saxena A, Mars LT, Domingues HS, Mentele R, Ben-Nun A, 
et al.  Myelin-specific T cells also recognize neuronal autoantigen in a transgenic 
mouse model of multiple sclerosis. Nat Med (2009) 15:626–32. doi:10.1038/
nm.1975 
 68. Haring JS, Pewe LL, Perlman S. Bystander CD8 T cell-mediated demyelination 
after viral infection of the central nervous system. J Immunol (2002) 169:1550–5. 
doi:10.4049/jimmunol.169.3.1550 
 69. Ji Q, Perchellet A, Goverman JM. Viral infection triggers central nervous system 
autoimmunity via activation of CD8+ T cells expressing dual TCRs. Nat Immunol 
(2010) 11:628–34. doi:10.1038/ni.1888 
 70. Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, Johner C, et al.  Commensal 
microbiota and myelin autoantigen cooperate to trigger autoimmune demye-
lination. Nature (2011) 479:538–41. doi:10.1038/nature10554 
 71. Klehmet J, Shive C, Guardia-Wolff R, Petersen I, Spack EG, Boehm BO, et al. 
T cell epitope spreading to myelin oligodendrocyte glycoprotein in HLA-DR4 
transgenic mice during experimental autoimmune encephalomyelitis. Clin 
Immunol (2004) 111:53–60. doi:10.1016/j.clim.2003.12.012 
 72. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoim-
munity to cryptic determinants of an autoantigen. Nature (1992) 358:155–7. 
doi:10.1038/358155a0 
 73. McFarland HI, Lobito AA, Johnson MM, Nyswaner JT, Frank JA, Palardy GR, 
et al.  Determinant spreading associated with demyelination in a nonhuman 
primate model of multiple sclerosis. J Immunol (1999) 162:2384–90. 
 74. Vanderlugt CL, Neville KL, Nikcevich KM, Eagar TN, Bluestone JA, Miller 
SD. Pathologic role and temporal appearance of newly emerging autoepitopes 
in relapsing experimental autoimmune encephalomyelitis. J Immunol (2000) 
164:670–8. doi:10.4049/jimmunol.164.2.670 
 75. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope spreading 
initiates in the CNS in two mouse models of multiple sclerosis. Nat Med (2005) 
11:335–9. doi:10.1038/nm1202 
 76. Miller SD, Vanderlugt CL, Begolka WS, Pao W, Yauch RL, Neville KL, et al. 
Persistent infection with Theiler’s virus leads to CNS autoimmunity via epitope 
spreading. Nat Med (1997) 3:1133–6. doi:10.1038/nm1097-1133 
 77. Ristori G, Giubilei F, Giunti D, Perna A, Gasperini C, Buttinelli C, et al.  Myelin 
basic protein intramolecular spreading without disease progression in a patient 
with multiple sclerosis. J Neuroimmunol (2000) 110:240–3. doi:10.1016/
S0165-5728(00)00342-8 
 78. Uccelli A, Ristori G, Giunti D, Seri M, Montesperelli C, Caroli F, et al.  Dynamics of 
the reactivity to MBP in multiple sclerosis. J Neurovirol (2000) 6(Suppl 2):S52–6. 
 79. Tuohy VK, Yu M, Weinstock-Guttman B, Kinkel RP. Diversity and plasticity of 
self recognition during the development of multiple sclerosis. J Clin Invest (1997) 
99:1682–90. doi:10.1172/JCI119331 
 80. Muraro PA, Wandinger K, Bielekova B, Gran B, Marques A, Utz U, et al.  Molecular 
tracking of antigen-specific T cell clones in neurological immune-mediated 
disorders. Brain (2003) 126:20–31. doi:10.1093/brain/awg021 
 81. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas 
L, et al.  Genetic risk and a primary role for cell-mediated immune mechanisms 
in multiple sclerosis. Nature (2011) 476:214–9. doi:10.1038/nature10251 
 82. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al.  Gene-
microarray analysis of multiple sclerosis lesions yields new targets validated 
in autoimmune encephalomyelitis. Nat Med (2002) 8:500–8. doi:10.1038/
nm0502-500 
 83. Madsen LS, Andersson EC, Jansson L, Krogsgaard M, Andersen CB, Engberg J, 
et al.  A humanized model for multiple sclerosis using HLA-DR2 and a human 
T-cell receptor. Nat Genet (1999) 23:343–7. doi:10.1038/15525 
 84. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, et al. 
Encephalitogenic potential of the myelin basic protein peptide (amino acids 
83-99) in multiple sclerosis: results of a phase II clinical trial with an altered 
peptide ligand. Nat Med (2000) 6:1167–75. doi:10.1038/80516 
 85. Nakajima H, Fukuda K, Doi Y, Sugino M, Kimura F, Hanafusa T, et al.  Expression 
of Th1/Th2-related chemokine receptors on peripheral T cells and correlation 
with clinical disease activity in patients with multiple sclerosis. Eur Neurol (2004) 
52:162–8. doi:10.1159/000081856 
 86. Shimizu Y, Ota K, Kubo S, Kabasawa C, Kobayashi M, Ohashi T, et al.  Association 
of Th1/Th2-related chemokine receptors in peripheral T cells with disease activity 
in patients with multiple sclerosis and neuromyelitis optica. Eur Neurol (2011) 
66:91–7. doi:10.1159/000329576 
 87. Tejada-Simon MV, Zang YC, Yang D, Hong J, Li S, Singh RA, et al.  Aberrant T cell 
responses to myelin antigens during clinical exacerbation in patients with mul-
tiple sclerosis. Int Immunol (2000) 12:1641–50. doi:10.1093/intimm/12.12.1641 
 88. Correale J, Gilmore W, McMillan M, Li S, McCarthy K, Le T, et al.  Patterns 
of cytokine secretion by autoreactive proteolipid protein-specific T cell clones 
during the course of multiple sclerosis. J Immunol (1995) 154:2959–68. 
 89. Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Reactivity pattern 
and cytokine profile of T cells primed by myelin peptides in multiple 
sclerosis and healthy individuals. Eur J Immunol (2001) 31:907–17. 
doi:10.1002/1521-4141(200103)31:3<907::AID-IMMU907>3.0.CO;2-1 
 90. Calabresi PA, Fields NS, Farnon EC, Frank JA, Bash CN, Kawanashi T, et al.  ELI-
spot of Th-1 cytokine secreting PBMC’s in multiple sclerosis: correlation with MRI 
lesions. J Neuroimmunol (1998) 85:212–9. doi:10.1016/S0165-5728(98)00008-3 
 91. Bielekova B, Sung M, Kadom N, Simon R, McFarland H, Martin R. 
Expansion and functional relevance of high-avidity myelin-specific CD4+ 
T cells in multiple sclerosis. J Immunol (2004) 172:3893–904. doi:10.4049/
jimmunol.172.6.3893 
 92. Lowther DE, Chong DL, Ascough S, Ettorre A, Ingram RJ, Boyton RJ, et al. 
Th1 not Th17 cells drive spontaneous MS-like disease despite a functional 
regulatory T cell response. Acta Neuropathol (2013) 126:501–15. doi:10.1007/
s00401-013-1159-9 
 93. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al.  Reciprocal 
developmental pathways for the generation of pathogenic effector TH17 and 
regulatory T cells. Nature (2006) 441:235–8. doi:10.1038/nature04753 
 94. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, et al.  IL-21 initiates 
an alternative pathway to induce proinflammatory TH17 cells. Nature (2007) 
448:484–7. doi:10.1038/nature05970 
 95. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, 
et al.  IL-23 drives a pathogenic T cell population that induces autoimmune 
inflammation. J Exp Med (2005) 201:233–40. doi:10.1084/jem.20041257 
 96. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, 
et al.  Human TH17 lymphocytes promote blood-brain barrier disruption and 
central nervous system inflammation. Nat Med (2007) 13:1173–5. doi:10.1038/
nm1651 
 97. Quan C, Yu H, Qiao J, Xiao B, Zhao G, Wu Z, et al.  Impaired regulatory function 
and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from 
multiple sclerosis. Mult Scler (2013) 19:289–98. doi:10.1177/1352458512454771 
 98. Darlington PJ, Touil T, Doucet J, Gaucher D, Zeidan J, Gauchat D, et al. 
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease 
abrogation after hematopoietic stem cell transplantation. Ann Neurol (2013) 
73:341–54. doi:10.1002/ana.23784 
 99. Venken K, Hellings N, Hensen K, Rummens J, Stinissen P. Memory 
CD4+CD127high T cells from patients with multiple sclerosis produce IL-17 in 
response to myelin antigens. J Neuroimmunol (2010) 226:185–91. doi:10.1016/j.
jneuroim.2010.05.025 
 100. Schlapbach C, Gehad A, Yang C, Watanabe R, Guenova E, Teague JE, et al.  Human 
TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory 
capacity. Sci Transl Med (2014) 6:219ra8. doi:10.1126/scitranslmed.3007828 
 101. Jager A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and 
Th9 effector cells induce experimental autoimmune encephalomyelitis with 
different pathological phenotypes. J Immunol (2009) 183:7169–77. doi:10.4049/
jimmunol.0901906 
 102. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al.  Th22 
cells represent a distinct human T cell subset involved in epidermal immunity 
and remodeling. J Clin Invest (2009) 119:3573–85. doi:10.1172/JCI40202 
 103. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of 
interleukin 22 but not interleukin 17 by a subset of human skin-homing memory 
T cells. Nat Immunol (2009) 10:857–63. doi:10.1038/ni.1767 
 104. Rolla S, Bardina V, De Mercanti S, Quaglino P, De Palma R, Gned D, et al.  Th22 
cells are expanded in multiple sclerosis and are resistant to IFN-β. J Leukoc Biol 
(2014) 96:1155–64. doi:10.1189/jlb.5A0813-463RR 
 105. Peelen E, Damoiseaux J, Smolders J, Knippenberg S, Menheere P, Tervaert 
JW, et al.  Th17 expansion in MS patients is counterbalanced by an expanded 
CD39+ regulatory T cell population during remission but not during relapse. J 
Neuroimmunol (2011) 240-241:97–103. doi:10.1016/j.jneuroim.2011.09.013 
June 2015 | Volume 6 | Article 32217
Riedhammer and Weissert Antigen presentation in multiple sclerosis
Frontiers in Immunology | www.frontiersin.org
 106. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional sup-
pression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. 
J Exp Med (2004) 199:971–9. doi:10.1084/jem.20031579 
 107. Haas J, Hug A, Viehöver A, Fritzsching B, Falk CS, Filser A, et al.  Reduced 
suppressive effect of CD4+CD25high regulatory T cells on the T cell immune 
response against myelin oligodendrocyte glycoprotein in patients with multiple 
sclerosis. Eur J Immunol (2005) 35:3343–52. doi:10.1002/eji.200526065 
 108. Feger U, Luther C, Poeschel S, Melms A, Tolosa E, Wiendl H. Increased frequency 
of CD4 + CD25 + regulatory T cells in the cerebrospinal fluid but not in the 
blood of multiple sclerosis patients. Clin Exp Immunol (2007) 147:412–8. 
doi:10.1111/j.1365-2249.2006.03271.x 
 109. Venken K, Hellings N, Hensen K, Rummens J, Medaer R, D’hooghe MB, et al. 
Secondary progressive in contrast to relapsing-remitting multiple sclerosis 
patients show a normal CD4 + CD25 + regulatory T-cell function and FOXP3 
expression. J Neurosci Res (2006) 83:1432–46. doi:10.1002/jnr.20852 
 110. Michel L, Berthelot L, Pettré S, Wiertlewski S, Lefrère F, Braudeau C, et al.  Patients 
with relapsing-remitting multiple sclerosis have normal Treg function when cells 
expressing IL-7 receptor α-chain are excluded from the analysis. J Clin Invest 
(2008) 118:3411–9. doi:10.1172/JCI35365 
 111. Frisullo G, Nociti V, Iorio R, Patanella AK, Caggiula M, Marti A, et al.  Regulatory 
T cells fail to suppress CD4 + T-bet + T cells in relapsing multiple sclerosis 
patients. Immunology (2009) 127:418–28. doi:10.1111/j.1365-2567.2008.02963.x 
 112. Kumar M, Putzki N, Limmroth V, Remus R, Lindemann M, Knop D, et al. 
CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein- 
induced proliferation in patients with multiple sclerosis. J Neuroimmunol (2006) 
180:178–84. doi:10.1016/j.jneuroim.2006.08.003 
 113. Venken K, Hellings N, Broekmans T, Hensen K, Rummens J, Stinissen P. 
Natural Naive CD4+CD25+CD127low regulatory T cell (Treg) development 
and function are disturbed in multiple sclerosis patients: recovery of memory 
Treg homeostasis during disease progression. J Immunol (2008) 180:6411–20. 
doi:10.4049/jimmunol.180.9.6411 
 114. Haas J, Fritzsching B, Trubswetter P, Korporal M, Milkova L, Fritz B, et al. 
Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg 
suppressive function and determines Treg dysfunction in multiple sclerosis. 
J Immunol (2007) 179:1322–30. doi:10.4049/jimmunol.179.2.1322 
 115. Hug A, Korporal M, Schroder I, Haas J, Glatz K, Storch-Hagenlocher B, et al. 
Thymic export function and T cell homeostasis in patients with relapsing remitting 
multiple sclerosis. J Immunol (2003) 171:432–7. doi:10.4049/jimmunol.171.1.432 
 116. Fletcher JM, Lonergan R, Costelloe L, Kinsella K, Moran B, O’Farrelly C, et al. 
CD39+Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are 
impaired in multiple sclerosis. J Immunol (2009) 183:7602–10. doi:10.4049/
jimmunol.0901881 
 117. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR, et al.  Myelin-
specific regulatory T cells accumulate in the CNS but fail to control autoimmune 
inflammation. Nat Med (2007) 13:423–31. doi:10.1038/nm1564 
 118. Gurevich M, Achiron A. The switch between relapse and remission in multiple 
sclerosis: continuous inflammatory response balanced by Th1 suppression and neuro-
trophic factors. J Neuroimmunol (2012) 252:83–8. doi:10.1016/j.jneuroim.2012.07.014 
 119. Herrmann MM, Gaertner S, Stadelmann C, van den Brandt J, Böscke R, Budach 
W, et al.  Tolerance induction by bone marrow transplantation in a multiple 
sclerosis model. Blood (2005) 106:1875–83. doi:10.1182/blood-2004-12-4607 
 120. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al.  Clonal 
expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple 
sclerosis lesions as shown by micromanipulation and single cell polymerase 
chain reaction. J Exp Med (2000) 192:393–404. doi:10.1084/jem.192.3.393 
 121. Skulina C, Schmidt S, Dornmair K, Babbe H, Roers A, Rajewsky K, et al.  Multiple 
sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the 
cerebrospinal fluid and blood. Proc Natl Acad Sci U S A (2004) 101:2428–33. 
doi:10.1073/pnas.0308689100 
 122. Sauer BM, Schmalstieg WF, Howe CL. Axons are injured by antigen-specific 
CD8+ T cells through a MHC class I- and granzyme B-dependent mechanism. 
Neurobiol Dis (2013) 59:194–205. doi:10.1016/j.nbd.2013.07.010 
 123. Zang YCQ, Li S, Rivera VM, Hong J, Robinson RR, Breitbach WT, et al.  Increased 
CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. 
J Immunol (2004) 172:5120–7. doi:10.4049/jimmunol.172.8.5120 
 124. Liu G, Fang L, Hjelmstrom P, Gao X. Increased CD8+ central memory 
T cells in patients with multiple sclerosis. Mult Scler (2007) 13:149–55. 
doi:10.1177/1352458506069246 
 125. Jacobsen M, Cepok S, Quak E, Happel M, Gaber R, Ziegler A, et al.  Oligoclonal 
expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis 
patients. Brain (2002) 125:538–50. doi:10.1093/brain/awf059 
 126. Malmestrom C, Lycke J, Haghighi S, Andersen O, Carlsson L, Wadenvik H, 
et al.  Relapses in multiple sclerosis are associated with increased CD8+ T-cell 
mediated cytotoxicity in CSF. J Neuroimmunol (2008) 196:159–65. doi:10.1016/j.
jneuroim.2008.03.001 
 127. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlén C, Goverman J. A pathogenic 
role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp 
Med (2001) 194:669–76. doi:10.1084/jem.194.5.669 
 128. Cunnusamy K, Baughman EJ, Franco J, Ortega SB, Sinha S, Chaudhary P, et al. 
Disease exacerbation of multiple sclerosis is characterized by loss of terminally 
differentiated autoregulatory CD8+ T cells. Clin Immunol (2014) 152:115–26. 
doi:10.1016/j.clim.2014.03.005 
 129. Baughman EJ, Mendoza JP, Ortega SB, Ayers CL, Greenberg BM, Frohman 
EM, et al.  Neuroantigen-specific CD8+ regulatory T-cell function is deficient 
during acute exacerbation of multiple sclerosis. J Autoimmun (2011) 36:115–24. 
doi:10.1016/j.jaut.2010.12.003 
 130. Correale J, Villa A. Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple 
sclerosis. Ann Neurol (2009) 67:625–38. doi:10.1002/ana.21944 
 131. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al.  B-cell 
depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 
(2008) 358:676–88. doi:10.1056/NEJMoa0706383 
 132. Link H, Huang Y. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: 
an update on methodology and clinical usefulness. J Neuroimmunol (2006) 
180:17–28. doi:10.1016/j.jneuroim.2006.07.006 
 133. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies 
associated with myelin damage in multiple sclerosis. Nat Med (1999) 5:170–5. 
doi:10.1038/5532 
 134. O’Connor KC, Appel H, Bregoli L, Call ME, Catz I, Chan JA, et al.  Antibodies 
from inflamed central nervous system tissue recognize myelin oligodendrocyte 
glycoprotein. J Immunol (2005) 175:1974–82. doi:10.4049/jimmunol.175.3.1974 
 135. Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, et al.  Abnormal 
B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 
(2010) 67:452–61. doi:10.1002/ana.21939 
 136. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 
(1985) 314:537–9. doi:10.1038/314537a0 
 137. Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod’homme T, 
Varrin-Doyer M, et al.  MHC class II-dependent B cell APC function is required 
for induction of CNS autoimmunity independent of myelin-specific antibodies. 
J Exp Med (2013) 210:2921–37. doi:10.1084/jem.20130699 
 138. Harp CT, Ireland S, Davis LS, Remington G, Cassidy B, Cravens PD, et al.  Memory 
B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis 
patients elicit CD4+ T-cell proliferation and IFN-γ production in response to 
myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol 
(2010) 40:2942–56. doi:10.1002/eji.201040516 
 139. Monson NL, Brezinschek H, Brezinschek RI, Mobley A, Vaughan GK, 
Frohman EM, et al.  Receptor revision and atypical mutational characteristics 
in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed 
multiple sclerosis patients. J Neuroimmunol (2005) 158:170–81. doi:10.1016/j.
jneuroim.2004.04.022 
 140. Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med 
(2000) 343:108–17. doi:10.1056/NEJM200007133430207 
 141. Kinnunen T, Chamberlain N, Morbach H, Cantaert T, Lynch M, Preston-Hurlburt 
P, et al.  Specific peripheral B cell tolerance defects in patients with multiple 
sclerosis. J Clin Invest (2013) 123:2737–41. doi:10.1172/JCI68775 
 142. Iwata Y, Matsushita T, Horikawa M, DiLillo DJ, Yanaba K, Venturi GM, et al. 
Characterization of a rare IL-10-competent B-cell subset in humans that 
parallels mouse regulatory B10 cells. Blood (2011) 117:530–41. doi:10.1182/
blood-2010-07-294249 
 143. Yoshizaki A, Miyagaki T, DiLillo DJ, Matsushita T, Horikawa M, Kountikov EI, 
et al.  Regulatory B cells control T-cell autoimmunity through IL-21-dependent 
cognate interactions. Nature (2012) 491:264–8. doi:10.1038/nature11501 
 144. Knippenberg S, Peelen E, Smolders J, Thewissen M, Menheere P, Cohen 
Tervaert JW, et al.  Reduction in IL-10 producing B cells (Breg) in multiple 
sclerosis is accompanied by a reduced naïve/memory Breg ratio during a 
relapse but not in remission. J Neuroimmunol (2011) 239:80–6. doi:10.1016/j.
jneuroim.2011.08.019 
June 2015 | Volume 6 | Article 32218
Riedhammer and Weissert Antigen presentation in multiple sclerosis
Frontiers in Immunology | www.frontiersin.org
 145. Michel L, Chesneau M, Manceau P, Genty A, Garcia A, Salou M, et al.  Unaltered 
regulatory B-cell frequency and function in patients with multiple sclerosis. Clin 
Immunol (2014) 155:198–208. doi:10.1016/j.clim.2014.09.011 
 146. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, et al.  Distinct 
effector cytokine profiles of memory and naive human B cell subsets and 
implication in multiple sclerosis. J Immunol (2007) 178:6092–9. doi:10.4049/
jimmunol.178.10.6092 
 147. Correale J, Farez M, Razzitte G. Helminth infections associated with multiple 
sclerosis induce regulatory B cells. Ann Neurol (2008) 64:187–99. doi:10.1002/
ana.21438 
 148. Cohn L, Delamarre L. Dendritic cell-targeted vaccines. Front Immunol (2014) 
5:255. doi:10.3389/fimmu.2014.00255 
 149. Burster T, Beck A, Tolosa E, Schnorrer P, Weissert R, Reich M, et al.  Differential 
processing of autoantigens in lysosomes from human monocyte-derived and 
peripheral blood dendritic cells. J Immunol (2005) 175:5940–9. doi:10.4049/
jimmunol.175.9.5940 
 150. Delamarre L, Mellman I. Harnessing dendritic cells for immunotherapy. Semin 
Immunol (2011) 23:2–11. doi:10.1016/j.smim.2011.02.001 
 151. Hertz CJ, Kiertscher SM, Godowski PJ, Bouis DA, Norgard MV, Roth MD, et al. 
Microbial lipopeptides stimulate dendritic cell maturation via toll-like receptor 
2. J Immunol (2001) 166:2444–50. doi:10.4049/jimmunol.166.4.2444 
 152. Mehta-Damani A, Markowicz S, Engleman EG. Generation of antigen-specific 
CD4+ T cell lines from naive precursors. Eur J Immunol (1995) 25:1206–11. 
doi:10.1002/eji.1830250511 
 153. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, 
et al.  Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cyto-
toxic T cell immunity. Science (2008) 322:1097–100. doi:10.1126/science.1164206 
 154. Karni A, Abraham M, Monsonego A, Cai G, Freeman GJ, Hafler D, et al.  Innate 
immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive 
multiple sclerosis are activated and drive a proinflammatory immune response. 
J Immunol (2006) 177:4196–202. doi:10.4049/jimmunol.177.6.4196 
 155. van Zwam M, Samsom JN, Nieuwenhuis EE, Melief M, Wierenga-Wolf AF, 
Dijke IE, et al.  Myelin ingestion alters macrophage antigen-presenting function 
in vitro and in vivo. J Leukoc Biol (2011) 90:123–32. doi:10.1189/jlb.1209813 
 156. Pesic M, Bartholomäus I, Kyratsous NI, Heissmeyer V, Wekerle H, Kawakami 
N. 2-photon imaging of phagocyte-mediated T cell activation in the CNS. J Clin 
Invest (2013) 123:1192–201. doi:10.1172/JCI67233 
 157. Fabriek BO, Van Haastert ES, Galea I, Polfliet MM, Döpp ED, Van Den Heuvel 
MM, et al.  CD163-positive perivascular macrophages in the human CNS express 
molecules for antigen recognition and presentation. Glia (2005) 51:297–305. 
doi:10.1002/glia.20208 
 158. Jack C, Ruffini F, Bar-Or A, Antel JP. Microglia and multiple sclerosis. J Neurosci 
Res (2005) 81:363–73. doi:10.1002/jnr.20482 
 159. Woodroofe MN, Bellamy AS, Feldmann M, Davison AN, Cuzner ML. 
Immunocytochemical characterisation of the immune reaction in the central 
nervous system in multiple sclerosis. Possible role for microglia in lesion growth. 
J Neurol Sci (1986) 74:135–52. doi:10.1016/0022-510X(86)90100-0 
 160. Bö L, Mörk S, Kong PA, Nyland H, Pardo CA, Trapp BD. Detection of MHC 
class II-antigens on macrophages and microglia, but not on astrocytes and 
endothelia in active multiple sclerosis lesions. J Neuroimmunol (1994) 51:135–46. 
doi:10.1016/0165-5728(94)90075-2 
 161. Kort JJ, Kawamura K, Fugger L, Weissert R, Forsthuber TG. Efficient presentation 
of myelin oligodendrocyte glycoprotein peptides but not protein by astrocytes 
from HLA-DR2 and HLA-DR4 transgenic mice. J Neuroimmunol (2006) 
173:23–34. doi:10.1016/j.jneuroim.2005.11.014 
 162. Ebers GC, Bulman DE, Sadovnick AD, Paty DW, Warren S, Hader W, et al. 
A population-based study of multiple sclerosis in twins. N Engl J Med (1986) 
315:1638–42. doi:10.1056/NEJM198612253152603 
 163. Hedstrom AK, Sundqvist E, Baarnhielm M, Nordin N, Hillert J, Kockum I, et al. 
Smoking and two human leukocyte antigen genes interact to increase the risk 
for multiple sclerosis. Brain (2011) 134:653–64. doi:10.1093/brain/awq371 
 164. Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas 
C, et al.  Analysis of immune-related loci identifies 48 new susceptibility variants 
for multiple sclerosis. Nat Genet (2013) 45:1353–60. doi:10.1038/ng.2770 
 165. Fugger L, Friese MA, Bell JI. From genes to function: the next challenge to 
understanding multiple sclerosis. Nat Rev Immunol (2009) 9:408–17. doi:10.1038/
nri2554 
 166. Hensiek AE, Sawcer SJ, Feakes R, Deans J, Mander A, Akesson E, et al.  HLA-DR 
15 is associated with female sex and younger age at diagnosis in multiple sclerosis. 
J Neurol Neurosurg Psychiatry (2002) 72:184–7. doi:10.1136/jnnp.72.2.184 
 167. Friese MA, Jakobsen KB, Friis L, Etzensperger R, Craner MJ, McMahon 
RM, et al.  Opposing effects of HLA class I molecules in tuning autoreactive 
CD8+ T cells in multiple sclerosis. Nat Med (2008) 14:1227–35. doi:10.1038/
nm.1881 
 168. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, 
et al.  Genome-wide association study of 14,000 cases of seven common diseases 
and 3,000 shared controls. Nature (2007) 447:661–78. doi:10.1038/nature05911 
 169. Gregersen PK, Kosoy R, Lee AT, Lamb J, Sussman J, McKee D, et al.  Risk for 
myasthenia gravis maps to a 151 Pro→Ala change in TNIP1 and to human 
leukocyte antigen-B*08. Ann Neurol (2012) 72:927–35. doi:10.1002/ana.23691 
 170. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An 
approach to understanding the molecular genetics of susceptibility to rheumatoid 
arthritis. Arthritis Rheum (1987) 30:1205–13. doi:10.1002/art.1780301102 
 171. Jones EY, Fugger L, Strominger JL, Siebold C. MHC class II proteins and disease: 
a structural perspective. Nat Rev Immunol (2006) 6:271–82. doi:10.1038/nri1805 
 172. Mohme M, Hotz C, Stevanovic S, Binder T, Lee J, Okoniewski M, et  al. 
HLA-DR15-derived self-peptides are involved in increased autologous T cell 
proliferation in multiple sclerosis. Brain (2013) 136:1783–98. doi:10.1093/brain/
awt108 
 173. Kirschmann DA, Duffin KL, Smith CE, Welply JK, Howard SC, Schwartz BD, 
et al.  Naturally processed peptides from rheumatoid arthritis associated and 
non-associated HLA-DR alleles. J Immunol (1995) 155:5655–62. 
 174. Moldovan IR, Rudick RA, Cotleur AC, Born SE, Lee J, Karafa MT, et al.  Interferon 
gamma responses to myelin peptides in multiple sclerosis correlate with a new 
clinical measure of disease progression. J Neuroimmunol (2003) 141:132–40. 
doi:10.1016/S0165-5728(03)00221-2 
 175. Olsson T, Sun J, Hillert J, Höjeberg B, Ekre HP, Andersson G, et al.  Increased 
numbers of T cells recognizing multiple myelin basic protein epitopes in multiple 
sclerosis. Eur J Immunol (1992) 22:1083–7. doi:10.1002/eji.1830220431 
 176. Hedegaard CJ, Krakauer M, Bendtzen K, Lund H, Sellebjerg F, Nielsen CH. 
T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein 
and disease activity in multiple sclerosis. Immunology (2008) 125:161–9. 
doi:10.1111/j.1365-2567.2008.02837.x 
 177. Valli A, Sette A, Kappos L, Oseroff C, Sidney J, Miescher G, et al.  Binding of 
myelin basic protein peptides to human histocompatibility leukocyte antigen 
class II molecules and their recognition by T cells from multiple sclerosis patients. 
J Clin Invest (1993) 91:616–28. doi:10.1172/JCI116242 
 178. Martin R, Howell MD, Jaraquemada D, Flerlage M, Richert J, Brostoff S, et al. 
A myelin basic protein peptide is recognized by cytotoxic T cells in the context 
of four HLA-DR types associated with multiple sclerosis. J Exp Med (1991) 
173:19–24. doi:10.1084/jem.173.1.19 
 179. Greer JM, Csurhes PA, Pender MP, McCombe PA. Effect of gender on T-cell 
proliferative responses to myelin proteolipid protein antigens in patients with 
multiple sclerosis and controls. J Autoimmun (2004) 22:345–52. doi:10.1016/j.
jaut.2004.03.004 
 180. Pender MP, Csurhes PA, Greer JM, Mowat PD, Henderson RD, Cameron 
KD, et al.  Surges of increased T cell reactivity to an encephalitogenic region 
of myelin proteolipid protein occur more often in patients with multiple 
sclerosis than in healthy subjects. J Immunol (2000) 165:5322–31. doi:10.4049/
jimmunol.165.9.5322 
 181. Greer JM, Csurhes PA, Cameron KD, McCombe PA, Good MF, Pender MP. 
Increased immunoreactivity to two overlapping peptides of myelin proteo-
lipid protein in multiple sclerosis. Brain (1997) 120:1447–60. doi:10.1093/
brain/120.8.1447 
 182. Krogsgaard M, Wucherpfennig KW, Cannella B, Hansen BE, Svejgaard A, 
Pyrdol J, et al.  Visualization of myelin basic protein (MBP) T cell epitopes in 
multiple sclerosis lesions using a monoclonal antibody specific for the human 
histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J Exp 
Med (2000) 191:1395–412. doi:10.1084/jem.191.8.1395 
 183. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, et al.  Induction of a 
non-encephalitogenic type 2 T helper-cell autoimmune response in multiple 
sclerosis after administration of an altered peptide ligand in a placebo-controlled, 
randomized phase II trial. The altered peptide ligand in relapsing MS study 
group. Nat Med (2000) 6:1176–82. doi:10.1038/80525 
June 2015 | Volume 6 | Article 32219
Riedhammer and Weissert Antigen presentation in multiple sclerosis
Frontiers in Immunology | www.frontiersin.org
 184. Vogt AB, Kropshofer H, Kalbacher H, Kalbus M, Rammensee HG, Coligan JE, 
et al.  Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated 
from self-peptides. J Immunol (1994) 153:1665–73. 
 185. Vergelli M, Kalbus M, Rojo SC, Hemmer B, Kalbacher H, Tranquill L, et al. 
T cell response to myelin basic protein in the context of the multiple sclero-
sis-associated HLA-DR15 haplotype: peptide binding, immunodominance and 
effector functions of T cells. J Neuroimmunol (1997) 77:195–203. doi:10.1016/
S0165-5728(97)00075-1 
 186. Belogurov A, Kudriaeva A, Kuzina E, Smirnov I, Bobik T, Ponomarenko N, et al. 
Multiple sclerosis autoantigen myelin basic protein escapes control by ubiq-
uitination during proteasomal degradation. J Biol Chem (2014) 289:17758–66. 
doi:10.1074/jbc.M113.544247 
 187. Pelfrey CM, Trotter JL, Tranquill LR, McFarland HF. Identification of a novel T cell 
epitope of human proteolipid protein (residues 40-60) recognized by proliferative 
and cytolytic CD4+ T cells from multiple sclerosis patients. J Neuroimmunol 
(1993) 46:33–42. doi:10.1016/0165-5728(93)90231-M 
 188. Pelfrey CM, Tranquill LR, Vogt AB, McFarland HF. T cell response to two 
immunodominant proteolipid protein (PLP) peptides in multiple sclerosis 
patients and healthy controls. Mult Scler (1996) 1:270–8. 
 189. Trotter JL, Pelfrey CM, Trotter AL, Selvidge JA, Gushleff KC, Mohanakumar T, 
et al.  T cell recognition of myelin proteolipid protein and myelin proteolipid 
protein peptides in the peripheral blood of multiple sclerosis and control subjects. 
J Neuroimmunol (1998) 84:172–8. doi:10.1016/S0165-5728(97)00260-9 
 190. Markovic-Plese S, Fukaura H, Zhang J, al-Sabbagh A, Southwood S, Sette A, 
et al.  T cell recognition of immunodominant and cryptic proteolipid protein 
epitopes in humans. J Immunol (1995) 155:982–92. 
 191. Trotter JL, Hickey WF, van der Veen RC, Sulze L. Peripheral blood mononuclear cells 
from multiple sclerosis patients recognize myelin proteolipid protein and selected 
peptides. J Neuroimmunol (1991) 33:55–62. doi:10.1016/0165-5728(91)90034-5 
 192. Sun J, Link H, Olsson T, Xiao BG, Andersson G, Ekre HP, et al.  T and B cell 
responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J 
Immunol (1991) 146:1490–5. 
 193. Wallström E, Khademi M, Andersson M, Weissert R, Linington C, Olsson T. Increased 
reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in 
HLA DR2(15)+ multiple sclerosis. Eur J Immunol (1998) 28:3329–35. doi:10.1002/
(SICI)1521-4141(199810)28:10<3329::AID-IMMU3329>3.0.CO;2-B 
 194. Raddassi K, Kent SC, Yang J, Bourcier K, Bradshaw EM, Seyfert-Margolis V, 
et al.  Increased frequencies of myelin oligodendrocyte glycoprotein/MHC 
class II-binding CD4 cells in patients with multiple sclerosis. J Immunol (2011) 
187:1039–46. doi:10.4049/jimmunol.1001543 
 195. Kerlero de Rosbo N, Milo R, Lees MB, Burger D, Bernard CC, Ben-Nun A. 
Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes 
respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 
(1993) 92:2602–8. doi:10.1172/JCI116875 
 196. Varrin-Doyer M, Shetty A, Spencer CM, Schulze-Topphoff U, Weber MS, 
Bernard CC, et al.  MOG transmembrane and cytoplasmic domains contain 
highly stimulatory T-cell epitopes in MS. Neurol Neuroimmunol Neuroinflamm 
(2014) 1:e20. doi:10.1212/NXI.0000000000000020 
 197. Kennel De March A, De Bouwerie M, Kolopp-Sarda MN, Faure GC, Béné 
MC, Bernard CC. Anti-myelin oligodendrocyte glycoprotein B-cell responses 
in multiple sclerosis. J Neuroimmunol (2003) 135:117–25. doi:10.1016/
S0165-5728(02)00434-4 
 198. Khalil M, Reindl M, Lutterotti A, Kuenz B, Ehling R, Gneiss C, et al.  Epitope 
specificity of serum antibodies directed against the extracellular domain of 
myelin oligodendrocyte glycoprotein: influence of relapses and immuno-
modulatory treatments. J Neuroimmunol (2006) 174:147–56. doi:10.1016/j.
jneuroim.2006.01.012 
 199. Lindert RB, Haase CG, Brehm U, Linington C, Wekerle H, Hohlfeld R. 
Multiple sclerosis: B- and T-cell responses to the extracellular domain of the 
myelin oligodendrocyte glycoprotein. Brain (1999) 122:2089–100. doi:10.1093/
brain/122.11.2089 
 200. Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Bruck W, et al. 
Identification of a pathogenic antibody response to native myelin oligodendrocyte 
glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 103:19057–62. 
doi:10.1073/pnas.0607242103 
 201. Lalive PH, Menge T, Delarasse C, Della Gaspera B, Pham-Dinh D, Villoslada P, 
et al.  Antibodies to native myelin oligodendrocyte glycoprotein are serologic 
markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 
(2006) 103:2280–5. doi:10.1073/pnas.0510672103 
 202. Probstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, et al. 
Antibodies to MOG are transient in childhood acute disseminated encepha-
lomyelitis. Neurology (2011) 77:580–8. doi:10.1212/WNL.0b013e318228c0b1 
 203. Gaertner S, de Graaf KL, Greve B, Weissert R. Antibodies against glycosylated 
native MOG are elevated in patients with multiple sclerosis. Neurology (2004) 
63:2381–3. doi:10.1212/01.WNL.0000147259.34163.33 
 204. Klawiter EC, Piccio L, Lyons J, Mikesell R, O’Connor KC, Cross AH. Elevated 
intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. 
Arch Neurol (2010) 67:1102–8. doi:10.1001/archneurol.2010.197 
 205. Karni A, Bakimer-Kleiner R, Abramsky O, Ben-Nun A. Elevated levels of 
antibody to myelin oligodendrocyte glycoprotein is not specific for patients with 
multiple sclerosis. Arch Neurol (1999) 56:311–5. doi:10.1001/archneur.56.3.311 
 206. Tomassini V, de Giglio L, Reindl M, Russo P, Pestalozza I, Pantano P, et al.  Anti-
myelin antibodies predict the clinical outcome after a first episode suggestive of 
MS. Mult Scler (2007) 13:1086–94. doi:10.1177/1352458507077622 
 207. Pelayo R, Tintoré M, Montalban X, Rovira A, Espejo C, Reindl M, et al. 
Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med 
(2007) 356:426–8. doi:10.1056/NEJMc062467 
 208. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, et al.  Antimyelin 
antibodies as a predictor of clinically definite multiple sclerosis after a first demy-
elinating event. N Engl J Med (2003) 349:139–45. doi:10.1056/NEJMoa022328 
 209. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung H, et al.  Lack of 
association between antimyelin antibodies and progression to multiple sclerosis. 
N Engl J Med (2007) 356:371–8. doi:10.1056/NEJMoa063602 
 210. Lim ET, Berger T, Reindl M, Dalton CM, Fernando K, Keir G, et al.  Anti-myelin 
antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler (2005) 
11:492–4. doi:10.1191/1352458505ms1187sr 
 211. Haase CG, Guggenmos J, Brehm U, Andersson M, Olsson T, Reindl M, et al.  The 
fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response 
in patients with multiple sclerosis and normal healthy controls. J Neuroimmunol 
(2001) 114:220–5. doi:10.1016/S0165-5728(00)00462-8 
 212. Koehler NK, Genain CP, Giesser B, Hauser SL. The human T cell response to 
myelin oligodendrocyte glycoprotein: a multiple sclerosis family-based study. 
J Immunol (2002) 168:5920–7. doi:10.4049/jimmunol.168.11.5920 
 213. Weissert R, Kuhle J, de Graaf KL, Wienhold W, Herrmann MM, Müller C, et al. 
High immunogenicity of intracellular myelin oligodendrocyte glycoprotein 
epitopes. J Immunol (2002) 169:548–56. doi:10.4049/jimmunol.169.1.548 
 214. Garcia-Vallejo JJ, Ilarregui JM, Kalay H, Chamorro S, Koning N, Unger WW, 
et al.  CNS myelin induces regulatory functions of DC-SIGN-expressing, 
antigen-presenting cells via cognate interaction with MOG. J Exp Med (2014) 
211:1465–83. doi:10.1084/jem.20122192 
 215. Van Noort JM, van Sechel AC, Bajramovic JJ, el Ouagmiri M, Polman CH, 
Lassmann H, et  al.  The small heat-shock protein alpha B-crystallin as 
candidate autoantigen in multiple sclerosis. Nature (1995) 375:798–801. 
doi:10.1038/375798a0 
 216. Rothbard JB, Zhao X, Sharpe O, Strohman MJ, Kurnellas M, Mellins ED, et al. 
Chaperone activity of α B-crystallin is responsible for its incorrect assignment as 
an autoantigen in multiple sclerosis. J Immunol (2011) 186:4263–8. doi:10.4049/
jimmunol.1003934 
 217. Fissolo N, Haag S, de Graaf KL, Drews O, Stevanovic S, Rammensee HG, et al. 
Naturally presented peptides on major histocompatibility complex I and II 
molecules eluted from central nervous system of multiple sclerosis patients. 
Mol Cell Proteomics (2009) 8:2090–101. doi:10.1074/mcp.M900001-MCP200 
 218. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 
(2002) 2:797–804. doi:10.1038/nri916 
 219. Almon RR, Andrew CG, Appel SH. Serum globulin in myasthenia gravis: 
inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science 
(1974) 186:55–7. doi:10.1126/science.186.4158.55 
 220. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody 
to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, 
and diagnostic value. Neurology (1976) 26:1054–9. doi:10.1212/WNL.26.11.1054 
 221. Toyka KV, Brachman DB, Pestronk A, Kao I. Myasthenia gravis: passive transfer 
from man to mouse. Science (1975) 190:397–9. doi:10.1126/science.1179220 
 222. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-
antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia 
June 2015 | Volume 6 | Article 32220
Riedhammer and Weissert Antigen presentation in multiple sclerosis
Frontiers in Immunology | www.frontiersin.org
gravis without acetylcholine receptor antibodies. Nat Med (2001) 7:365–8. 
doi:10.1038/85520 
 223. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, et al.  IgG1 antibodies 
to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain (2008) 
131:1940–52. doi:10.1093/brain/awn092 
 224. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density 
lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol (2011) 
69:418–22. doi:10.1002/ana.22312 
 225. Hohlfeld R, Toyka KV, Heininger K, Grosse-Wilde H, Kalies I. Autoimmune 
human T lymphocytes specific for acetylcholine receptor. Nature (1984) 
310:244–6. doi:10.1038/310244a0 
 226. Balandina A, Lécart S, Dartevelle P, Saoudi A, Berrih-Aknin S. Functional defect 
of regulatory CD4+CD25+ T cells in the thymus of patients with autoimmune 
myasthenia gravis. Blood (2005) 105:735–41. doi:10.1182/blood-2003-11-3900 
 227. Hohlfeld R, Michels M, Tesch H, Fahsbender A, Heininger K, Conti-Tronconi 
BM, et al.  Epstein-Barr virus-transformed B cells can present acetylcholine 
receptor to autologous autoreactive T cells. Immunol Lett (1986) 12:171–4. 
doi:10.1016/0165-2478(86)90101-X 
 228. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. 
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 66:1485–9. 
doi:10.1212/01.wnl.0000216139.44259.74 
 229. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, 
et al.  A serum autoantibody marker of neuromyelitis optica: distinction from mul-
tiple sclerosis. Lancet (2004) 364:2106–12. doi:10.1016/S0140-6736(04)17551-X 
 230. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of 
optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp 
Med (2005) 202:473–7. doi:10.1084/jem.20050304 
 231. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti 
CF, et al.  Neuromyelitis optica IgG predicts relapse after longitudinally extensive 
transverse myelitis. Ann Neurol (2006) 59:566–9. doi:10.1002/ana.20770 
 232. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, et al. 
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromy-
elitis optica from multiple sclerosis. Brain (2007) 130:1194–205. doi:10.1093/
brain/awl371 
 233. Sabater L, Giralt A, Boronat A, Hankiewicz K, Blanco Y, Llufriu S, et al.  Cytotoxic 
effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro 
study. J Neuroimmunol (2009) 215:31–5. doi:10.1016/j.jneuroim.2009.07.014 
 234. Brück W, Popescu B, Lucchinetti CF, Markovic-Plese S, Gold R, Thal DR, et al. 
Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. 
Ann Neurol (2012) 72:385–94. doi:10.1002/ana.23621 
 235. Vincent T, Saikali P, Cayrol R, Roth AD, Bar-Or A, Prat A, et al.  Functional 
consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain 
barrier permeability and granulocyte recruitment. J Immunol (2008) 181:5730–7. 
doi:10.4049/jimmunol.181.8.5730 
 236. Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupree C, et al.  Intrathecal 
pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 
(2009) 66:617–29. doi:10.1002/ana.21802 
 237. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et  al. 
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann 
Neurol (2009) 66:630–43. doi:10.1002/ana.21837 
 238. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, 
Takahashi T, et al.  Distinction between MOG antibody-positive and AQP4 
antibody-positive NMO spectrum disorders. Neurology (2014) 82:474–81. 
doi:10.1212/WNL.0000000000000101 
 239. Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et  al. 
Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligo-
dendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol (2014) 
71:276–83. doi:10.1001/jamaneurol.2013.5857 
 240. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. 
Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human 
complement produces neuromyelitis optica lesions in mice. Brain (2010) 
133:349–61. doi:10.1093/brain/awp309 
 241. Asavapanumas N, Verkman AS. Neuromyelitis optica pathology in rats following 
intraperitoneal injection of NMO-IgG and intracerebral needle injury. Acta 
Neuropathol Commun (2014) 2:48. doi:10.1186/2051-5960-2-48 
 242. Linhares UC, Schiavoni PB, Barros PO, Kasahara TM, Teixeira B, Ferreira TB, 
et al.  The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly 
associated with neurological disability in neuromyelitis optica patients. J Clin 
Immunol (2013) 33:179–89. doi:10.1007/s10875-012-9780-2 
 243. Matsuya N, Komori M, Nomura K, Nakane S, Fukudome T, Goto H, et al. 
Increased T-cell immunity against aquaporin-4 and proteolipid protein in 
neuromyelitis optica. Int Immunol (2011) 23:565–73. doi:10.1093/intimm/dxr056 
 244. Van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immu-
nology, and therapeutic strategies. Physiol Rev (2011) 91:79–118. doi:10.1152/
physrev.00003.2010 
 245. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, et al.  Autoreactive 
T cell responses show proinflammatory polarization in diabetes but a regulatory 
phenotype in health. J Clin Invest (2004) 113(3):451–63. doi:10.1172/JCI19585 
 246. Marwaha AK, Crome SQ, Panagiotopoulos C, Berg KB, Qin H, Ouyang Q, et al. 
Cutting edge: increased IL-17-secreting T cells in children with new-onset type 
1 diabetes. J Immunol (2010) 185:3814–8. doi:10.4049/jimmunol.1001860 
 247. Honkanen J, Nieminen JK, Gao R, Luopajarvi K, Salo HM, Ilonen J, et al.  IL-17 
immunity in human type 1 diabetes. J Immunol (2010) 185:1959–67. doi:10.4049/
jimmunol.1000788 
 248. Ferraro A, Socci C, Stabilini A, Valle A, Monti P, Piemonti L, et al.  Expansion 
of Th17 cells and functional defects in T regulatory cells are key features of 
the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes (2011) 
60:2903–13. doi:10.2337/db11-0090 
 249. Pinkse GG, Tysma OH, Bergen CA, Kester MG, Ossendorp F, van Veelen PA, 
et al.  Autoreactive CD8 T cells associated with cell destruction in type 1 diabetes. 
Proc Natl Acad Sci U S A (2005) 102:18425–30. doi:10.1073/pnas.0508621102 
 250. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective 
suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 
diabetes. Diabetes (2005) 54:92–9. doi:10.2337/diabetes.54.1.92 
 251. Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH. 
The effector T cells of diabetic subjects are resistant to regulation via CD4+ 
FOXP3+ regulatory T cells. J Immunol (2008) 181:7350–5. doi:10.4049/
jimmunol.181.10.7350 
 252. Brooks-Worrell B, Gersuk VH, Greenbaum C, Palmer JP. Intermolecular anti-
gen spreading occurs during the preclinical period of human type 1 diabetes. 
 J Immunol (2001) 166:5265–70. doi:10.4049/jimmunol.166.8.5265 
 253. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, et al.  Insulin 
antibodies in insulin-dependent diabetics before insulin treatment. Science (1983) 
222:1337–9. doi:10.1126/science.6362005 
 254. Toma A, Haddouk S, Briand J, Camoin L, Gahery H, Connan F, et al.  Recognition 
of a subregion of human proinsulin by class I-restricted T cells in type 1 
diabetic patients. Proc Natl Acad Sci U S A (2005) 102:10581–6. doi:10.1073/
pnas.0504230102 
 255. Bonifacio E, Bingley PJ, Shattock M, Dean BM, Dunger D, Gale EA, et al. 
Quantification of islet-cell antibodies and prediction of insulin-dependent 
diabetes. Lancet (1990) 335:147–9. doi:10.1016/0140-6736(90)90013-U 
 256. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, 
et al.  Identification of the 64K autoantigen in insulin-dependent diabetes as 
the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature (1990) 
347:151–6. doi:10.1038/347151a0 
 257. Bonifacio E, Lampasona V, Genovese S, Ferrari M, Bosi E. Identification of 
protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-de-
pendent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. 
J Immunol (1995) 155:5419–26. 
 258. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, et al.  The cation efflux 
transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. 
Proc Natl Acad Sci U S A (2007) 104:17040–5. doi:10.1073/pnas.0705894104 
 259. Peakman M, Stevens EJ, Lohmann T, Narendran P, Dromey J, Alexander A, et al. 
Naturally processed and presented epitopes of the islet cell autoantigen IA-2 
eluted from HLA-DR4. J Clin Invest (1999) 104:1449–57. doi:10.1172/JCI7936 
 260. Nepom GT, Lippolis JD, White FM, Masewicz S, Marto JA, Herman A, et al. 
Identification and modulation of a naturally processed T cell epitope from the dia-
betes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65). 
Proc Natl Acad Sci U S A (2001) 98:1763–8. doi:10.1073/pnas.98.4.1763 
 261. Honeyman MC, Cram DS, Harrison LC. Glutamic acid decarboxylase 67-reactive 
T cells: a marker of insulin-dependent diabetes. J Exp Med (1993) 177:535–40. 
doi:10.1084/jem.177.2.535 
 262. Reijonen H, Mallone R, Heninger A, Laughlin EM, Kochik SA, Falk B, et al. 
GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in 
June 2015 | Volume 6 | Article 32221
Riedhammer and Weissert Antigen presentation in multiple sclerosis
Frontiers in Immunology | www.frontiersin.org
peripheral blood of patients with type 1 diabetes. Diabetes (2004) 53:1987–94. 
doi:10.2337/diabetes.53.8.1987 
 263. Dang M, Rockell J, Wagner R, Wenzlau JM, Yu L, Hutton JC, et al.  Human type 1 
diabetes is associated with T cell autoimmunity to zinc transporter 8. J Immunol 
(2011) 186:6056–63. doi:10.4049/jimmunol.1003815 
 264. Jarchum I, Nichol L, Trucco M, Santamaria P, DiLorenzo TP. Identification of 
novel IGRP epitopes targeted in type 1 diabetes patients. Clin Immunol (2008) 
127:359–65. doi:10.1016/j.clim.2008.01.015 
 265. Gottlieb PA, Delong T, Baker RL, Fitzgerald-Miller L, Wagner R, Cook G, et al. 
Chromogranin A is a T cell antigen in human type 1 diabetes. J Autoimmun 
(2014) 50:38–41. doi:10.1016/j.jaut.2013.10.003 
 266. von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting 
disease? Nat Rev Immunol (2007) 7:988–94. doi:10.1038/nri2192 
 267. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation 
in rheumatoid synovium is B cell dependent. J Immunol (2001) 167:4710–8. 
doi:10.4049/jimmunol.167.8.4710 
 268. Shiokawa S, Matsumato N, Nishimura J. Clonal analysis of B cells in the synovial 
membrane of patients with rheumatoid arthritis. Scand J Rheumatol (2003) 
32:12–8. doi:10.1080/03009740310000346 
 269. Yamada H, Nakashima Y, Okazaki K, Mawatari T, Fukushi J, Kaibara N, et al. 
Th1 but not Th17 cells predominate in the joints of patients with rheumatoid 
arthritis. Ann Rheum Dis (2007) 67:1299–304. doi:10.1136/ard.2007.080341 
 270. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, et al. 
Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum (2010) 
62:2876–85. doi:10.1002/art.27622 
 271. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, et al. 
IL-17 stimulates the production and expression of proinflammatory cytokines, 
IL-beta and TNF-alpha, by human macrophages. J Immunol (1998) 160:3513–21. 
 272. Van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, Hazes JM, 
et al.  Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis 
are potent inducers of matrix metalloproteinases and proinflammatory cytokines 
upon synovial fibroblast interaction, including autocrine interleukin-17A 
production. Arthritis Rheum (2011) 63:73–83. doi:10.1002/art.30093 
 273. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. 
Compromised function of regulatory T cells in rheumatoid arthritis and 
reversal by anti-TNFalpha therapy. J Exp Med (2004) 200:277–85. doi:10.1084/
jem.20040165 
 274. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, 
Close DR, et al.  Efficacy of B-cell-targeted therapy with rituximab in patients 
with rheumatoid arthritis. N Engl J Med (2004) 350:2572–81. doi:10.1056/
NEJMoa032534 
 275. Verheijden GF, Rijnders AW, Bos E, Coenen-de Roo CJ, van Staveren CJ, 
Miltenburg AM, et al.  Human cartilage glycoprotein-39 as a candidate autoan-
tigen in rheumatoid arthritis. Arthritis Rheum (1997) 40:1115–25. doi:10.1002/
art.1780400616 
 276. Li NL, Zhang DQ, Zhou KY, Cartman A, Leroux JY, Poole AR, et al.  Isolation 
and characteristics of autoreactive T cells specific to aggrecan G1 domain from 
rheumatoid arthritis patients. Cell Res (2000) 10:39–49. doi:10.1038/sj.cr.7290034 
 277. Franklin EC, Holman HR, Muller-Eberhard HJ, Kunkel HG. An unusual protein 
component of high molecular weight in the serum of certain patients with 
rheumatoid arthritis. J Exp Med (1957) 105:425–38. doi:10.1084/jem.105.5.425 
 278. Van Zeben D, Hazes JM, Zwinderman AH, Cats A, van der Voort EA, Breedveld 
FC. Clinical significance of rheumatoid factors in early rheumatoid arthritis: 
results of a follow up study. Ann Rheum Dis (1992) 51:1029–35. doi:10.1136/
ard.51.9.1029 
 279. Oda A, Miyata M, Kodama E, Satoh H, Sato Y, Nishimaki T, et al.  Antibodies to 
65Kd heat-shock protein were elevated in rheumatoid arthritis. Clin Rheumatol 
(1994) 13:261–4. 
 280. Trouw LA, Huizinga TW, Toes RE. Autoimmunity in rheumatoid arthritis: 
different antigens – common principles. Ann Rheum Dis (2013) 72(Suppl 2):ii132. 
doi:10.1136/annrheumdis-2012-202349 
 281. Brink M, Hansson M, Mathsson L, Jakobsson P, Holmdahl R, Hallmans G, et al. 
Multiplex analyses of antibodies against citrullinated peptides in individuals prior 
to development of rheumatoid arthritis. Arthritis Rheum (2013) 65:899–910. 
doi:10.1002/art.37835 
 282. Amara K, Steen J, Murray F, Morbach H, Fernandez-Rodriguez BM, Joshua V, 
et al.  Monoclonal IgG antibodies generated from joint-derived B cells of RA 
patients have a strong bias toward citrullinated autoantigen recognition. J Exp 
Med (2013) 210:445–55. doi:10.1084/jem.20121486 
 283. Van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, Onnekink C, 
Schwarte CM, Verpoort KN, et al.  Epitope spreading of the anti-citrullinated 
protein antibody response occurs before disease onset and is associated with the 
disease course of early arthritis. Ann Rheum Dis (2010) 69:1554–61. doi:10.1136/
ard.2009.124537 
 284. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, et al. 
Antibodies against citrullinated proteins enhance tissue injury in experimental 
autoimmune arthritis. J Clin Invest (2006) 116:961–73. doi:10.1172/JCI25422 
 285. Trouw LA, Haisma EM, Levarht EW, van der Woude D, Ioan-Facsinay A, Daha 
MR, et al.  Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis 
patients activate complement via both the classical and alternative pathways. 
Arthritis Rheum (2009) 60:1923–31. doi:10.1002/art.24622 
 286. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, 
et al.  Autoantibodies recognizing carbamylated proteins are present in sera of 
patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci 
U S A (2011) 108:17372–7. doi:10.1073/pnas.1114465108 
 287. Strollo R, Ponchel F, Malmström V, Rizzo P, Bombardieri M, Wenham CY, et al. 
Autoantibodies to posttranslationally modified type II collagen as potential 
biomarkers for rheumatoid arthritis. Arthritis Rheum (2013) 65:1702–12. 
doi:10.1002/art.37964 
 288. Rowley M, Tait B, Mackay IR, Cunningham T, Phillips B. Collagen antibodies in 
rheumatoid arthritis. Significance of antibodies to denatured collagen and their 
association with HLA-DR4. Arthritis Rheum (1986) 29:174–84. doi:10.1002/
art.1780290204 
 289. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases 
of the CNS: new developments and future challenges. Lancet Neurol (2011) 
10:759–72. doi:10.1016/S1474-4422(11)70096-5 
 290. Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ. Acute 
mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor 
encephalitis. Ann Neurol (2014) 76:108–19. doi:10.1002/ana.24195 
 291. Dalmau J, Tüzün E, Wu H, Masjuan J, Rossi JE, Voloschin A, et al.  Paraneoplastic 
anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian 
teratoma. Ann Neurol (2007) 61:25–36. doi:10.1002/ana.21050 
 292. Tüzün E, Zhou L, Baehring JM, Bannykh S, Rosenfeld MR, Dalmau J. Evidence 
for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated 
with ovarian teratoma. Acta Neuropathol (2009) 118:737–43. doi:10.1007/
s00401-009-0582-4 
 293. Voltz R, Dalmau J, Posner JB, Rosenfeld MR. T-cell receptor analysis in anti-Hu 
associated paraneoplastic encephalomyelitis. Neurology (1998) 51:1146–50. 
doi:10.1212/WNL.51.4.1146 
 294. Roberts WK, Deluca IJ, Thomas A, Fak J, Williams T, Buckley N, et al.  Patients 
with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 
CD8+ T cells. J Clin Invest (2009) 119:2042–51. doi:10.1172/JCI36131 
 295. Nakanishi K, Komatsu Y, Kogawa N, Matsushita H. Analysis of eluted peptides 
from type 1 diabetes-susceptible HLA class II molecules identified novel islet 
protein, heparin/heparan sulfate-interacting protein. Biochem Biophys Res 
Commun (2005) 329:356–61. doi:10.1016/j.bbrc.2005.01.144 
 296. De Graaf KL, Albert M, Weissert R. Autoantigen conformation influences both B- 
and T-cell responses and encephalitogenicity. J Biol Chem (2012) 287:17206–13. 
doi:10.1074/jbc.M111.304246 
 297. Wordsworth BP, Lanchbury JS, Sakkas LI, Welsh KI, Panayi GS, Bell JI. HLA-DR4 
subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major 
susceptibility locus within the HLA class II region. Proc Natl Acad Sci U S A 
(1989) 86:10049–53. doi:10.1073/pnas.86.24.10049 
 298. Nepom GT, Byers P, Seyfried C, Healey LA, Wilske KR, Stage D, et al.  HLA genes 
associated with rheumatoid arthritis. Identification of susceptibility alleles using 
specific oligonucleotide probes. Arthritis Rheum (1989) 32:15–21. doi:10.1002/
anr.1780320104 
 299. Carthy D, Ollier W, Papasteriades C, Pappas H, Thomson W. A shared HLA-
DRB1 sequence confers RA susceptibility in Greeks. Eur J Immunogenet (1993) 
20:391–8. doi:10.1111/j.1744-313X.1993.tb00158.x 
 300. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, 
Alexander HC, et al.  A missense single-nucleotide polymorphism in a gene 
encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid 
arthritis. Am J Hum Genet (2004) 75:330–7. doi:10.1086/422827 
June 2015 | Volume 6 | Article 32222
Riedhammer and Weissert Antigen presentation in multiple sclerosis
Frontiers in Immunology | www.frontiersin.org
 301. Cucca F, Lampis R, Congia M, Angius E, Nutland S, Bain SC, et al.  A correlation 
between the relative predisposition of MHC class II alleles to type 1 diabetes and 
the structure of their proteins. Hum Mol Genet (2001) 10:2025–37. doi:10.1093/
hmg/10.19.2025 
 302. Todd JA, Bell JI, McDevitt HO. HLA-DQ beta gene contributes to suscepti-
bility and resistance to insulin-dependent diabetes mellitus. Nature (1987) 
329:599–604. doi:10.1038/329599a0 
 303. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, et al. 
A functional variant of lymphoid tyrosine phosphatase is associated with type 
I diabetes. Nat Genet (2004) 36:337–8. doi:10.1038/ng1323 
 304. Vella A, Cooper JD, Lowe CE, Walker N, Nutland S, Widmer B, et al.  Localization 
of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucle-
otide polymorphisms. Am J Hum Genet (2005) 76:773–9. doi:10.1086/429843 
 305. Nisticò L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovannini C, Bosi E, 
et al.  The CTLA-4 gene region of chromosome 2q33 is linked to, and associated 
with, type 1 diabetes. Belgian diabetes registry. Hum Mol Genet (1996) 5:1075–80. 
doi:10.1093/hmg/5.7.1075 
 306. Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ, et al.  A genome-wide 
association study of nonsynonymous SNPs identifies a type 1 diabetes locus in 
the interferon-induced helicase (IFIH1) region. Nat Genet (2006) 38:617–9. 
doi:10.1038/ng1800 
 307. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, et al.  Robust 
associations of four new chromosome regions from genome-wide analyses of 
type 1 diabetes. Nat Genet (2007) 39:857–64. doi:10.1038/ng2068 
 308. Barratt BJ, Payne F, Lowe CE, Hermann R, Healy BC, Harold D, et al.  Remapping 
the insulin gene/IDDM2 locus in type 1 diabetes. Diabetes (2004) 53:1884–9. 
doi:10.2337/diabetes.53.7.1884 
 309. Matsushita T, Matsuoka T, Isobe N, Kawano Y, Minohara M, Shi N, et al. 
Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody posi-
tivity in Japanese patients with idiopathic central nervous system demyelinating 
disorders. Tissue Antigens (2009) 73:171–6. doi:10.1111/j.1399-0039.2008.01172.x 
 310. Zephir H, Fajardy I, Outteryck O, Blanc F, Roger N, Fleury M, et al.  Is neu-
romyelitis optica associated with human leukocyte antigen? Mult Scler (2009) 
15:571–9. doi:10.1177/1352458508102085 
 311. Quintana FJ, Farez MF, Izquierdo G, Lucas M, Cohen IR, Weiner HL. Antigen 
microarrays identify CNS-produced autoantibodies in RRMS. Neurology (2012) 
78:532–9. doi:10.1212/WNL.0b013e318247f9f3 
 312. Andersson M, Yu M, Söderström M, Weerth S, Baig S, Solders G, et  al. 
Multiple MAG peptides are recognized by circulating T and B lymphocytes 
in polyneuropathy and multiple sclerosis. Eur J Neurol (2002) 9:243–51. 
doi:10.1046/j.1468-1331.2002.00391.x 
 313. Kerlero de Rosbo N, Kaye JF, Eisenstein M, Mendel I, Hoeftberger R, Lassmann H, 
et al.  The myelin-associated oligodendrocytic basic protein region MOBP15-36 
encompasses the immunodominant major encephalitogenic epitope(s) for SJL/J 
mice and predicted epitope(s) for multiple sclerosis-associated HLA-DRB1*1501. 
J Immunol (2004) 173:1426–35. doi:10.4049/jimmunol.173.2.1426 
 314. Muraro PA, Kalbus M, Afshar G, McFarland HF, Martin R. T cell response to 
2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNPase) in multiple sclerosis patients. 
J Neuroimmunol (2002) 130:233–42. doi:10.1016/S0165-5728(02)00229-1 
 315. Schmidt S, Linington C, Zipp F, Sotgiu S, de Waal Malefyt R, Wekerle H, et al. 
Multiple sclerosis: comparison of the human T-cell response to S100 beta and 
myelin basic protein reveals parallels to rat experimental autoimmune panen-
cephalitis. Brain (1997) 120:1437–45. doi:10.1093/brain/120.8.1437 
 316. Banki K, Colombo E, Sia F, Halladay D, Mattson DH, Tatum AH, et  al. 
Oligodendrocyte-specific expression and autoantigenicity of transaldolase in 
multiple sclerosis. J Exp Med (1994) 180:1649–63. doi:10.1084/jem.180.5.1649 
 317. Pevzner A, Schoser B, Peters K, Cosma N, Karakatsani A, Schalke B, et al.  Anti-
LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. 
J Neurol (2012) 259:427–35. doi:10.1007/s00415-011-6194-7 
 318. Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, et al. 
Encephalitis with refractory seizures, status epilepticus, and antibodies to the 
GABAA receptor: a case series, characterisation of the antigen, and analysis 
of the effects of antibodies. Lancet Neurol (2014) 13:276–86. doi:10.1016/
S1474-4422(13)70299-0 
 319. Boronat A, Gelfand JM, Gresa-Arribas N, Jeong H, Walsh M, Roberts K, et al. 
Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of 
Kv4.2 potassium channels. Ann Neurol (2013) 73:120–8. doi:10.1002/ana.23756 
 320. Lancaster E, Martinez-Hernandez E, Titulaer MJ, Boulos M, Weaver S, Antoine J, 
et al.  Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. 
Neurology (2011) 77:1698–701. doi:10.1212/WNL.0b013e3182364a44 
 321. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu – associated paraneo-
plastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. 
Medicine (1992) 71:59–72. doi:10.1097/00005792-199203000-00001 
 322. Tanaka M, Maruyama Y, Sugie M, Motizuki H, Kamakura K, Tanaka K. Cytotoxic 
T cell activity against peptides of Hu protein in anti-Hu syndrome. J Neurol Sci 
(2002) 201:9–12. doi:10.1016/S0022-510X(02)00157-0 
 323. Greenlee JE, Brashear HR. Antibodies to cerebellar Purkinje cells in patients 
with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol 
(1983) 14:609–13. doi:10.1002/ana.410140603 
 324. Jaeckle KA, Graus F, Houghton A, Cardon-Cardo C, Nielsen SL, Posner JB. 
Autoimmune response of patients with paraneoplastic cerebellar degeneration 
to a Purkinje cell cytoplasmic protein antigen. Ann Neurol (1985) 18:592–600. 
doi:10.1002/ana.410180513 
 325. Luque FA, Furneaux HM, Ferziger R, Rosenblum MK, Wray SH, Schold SC, 
et al.  Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast 
cancer. Ann Neurol (1991) 29:241–51. doi:10.1002/ana.410290303 
 326. Dalmau J, Gultekin SH, Voltz R, Hoard R, DesChamps T, Balmaceda C, et al. 
Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of 
patients with paraneoplastic neurological disorders. Brain (1999) 122:27–39. 
doi:10.1093/brain/122.1.27 
 327. Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. 
Clinical analysis of anti-Ma2-associated encephalitis. Brain (2004) 127:1831–44. 
doi:10.1093/brain/awh203 
 328. Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J. Antibodies to 
Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 
(2004) 62:778–82. doi:10.1212/01.WNL.0000113749.77217.01 
 329. Kim J, Namchuk M, Bugawan T, Fu Q, Jaffe M, Shi Y, et al.  Higher autoantibody 
levels and recognition of a linear NH2-terminal epitope in the autoantigen 
GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes 
mellitus. J Exp Med (1994) 180:595–606. doi:10.1084/jem.180.2.595 
 330. Monstad SE, Nøstbakken JK, Vedeler CA. CRMP5 antibodies found in a patient 
with limbic encephalitis and myasthenia gravis. J Neurol Neurosurg Psychiatry 
(2009) 80:241–2. doi:10.1136/jnnp.2008.149336 
 331. Antoine JC, Absi L, Honnorat J, Boulesteix JM, de Brouker T, Vial C, et al. 
Antiamphiphysin antibodies are associated with various paraneoplastic neu-
rological syndromes and tumors. Arch Neurol (1999) 56:172–7. doi:10.1001/
archneur.56.2.172 
 332. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types 
of murine helper T cell clone. I. Definition according to profiles of lymphokine 
activities and secreted proteins. J Immunol (1986) 136:2348–57. 
 333. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. 
Cell (2000) 101:455–8. doi:10.1016/S0092-8674(00)80856-9 
 334. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher 
LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma 
production in CD4 and CD8 T cells. Science (2002) 295:338–42. doi:10.1126/
science.1065543 
 335. Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med (2000) 
343:37–49. doi:10.1056/NEJM200007063430107 
 336. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and suffi-
cient for Th2 cytokine gene expression in CD4 T cells. Cell (1997) 89:587–96. 
doi:10.1016/S0092-8674(00)80240-8 
 337. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of 
T(H)17 cells. Nature (2008) 453:1051–7. doi:10.1038/nature07036 
 338. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. 
The orphan nuclear receptor RORγt directs the differentiation program of 
proinflammatory IL-17+ T helper cells. Cell (2006) 126:1121–33. doi:10.1016/j.
cell.2006.07.035 
 339. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development 
by the transcription factor Foxp3. Science (2003) 299:1057–61. doi:10.1126/
science.1079490 
 340. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, et al.  IL-4 inhib-
its TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ 
IL-10+ Foxp3- effector T cells. Nat Immunol (2008) 9:1347–55. doi:10.1038/
ni.1677 
June 2015 | Volume 6 | Article 32223
Riedhammer and Weissert Antigen presentation in multiple sclerosis
Frontiers in Immunology | www.frontiersin.org
 341. Chang H, Sehra S, Goswami R, Yao W, Yu Q, Stritesky GL, et al.  The tran-
scription factor PU.1 is required for the development of IL-9-producing 
T cells and allergic inflammation. Nat Immunol (2010) 11:527–34. doi:10.1038/
ni.1867 
 342. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, et al. 
Transforming growth factor-β ‘reprograms’ the differentiation of T helper 2 cells 
and promotes an interleukin 9–producing subset. Nat Immunol (2008) 9:1341–6. 
doi:10.1038/ni.1659 
 343. Kaplan MH, Hufford MM, Olson MR. The development and in vivo func-
tion of T helper 9 cells. Nat Rev Immunol (2015) 15:295–307. doi:10.1038/
nri3824 
 344. Ramirez J, Brembilla NC, Sorg O, Chicheportiche R, Matthes T, Dayer J, et al. 
Activation of the aryl hydrocarbon receptor reveals distinct requirements for 
IL-22 and IL-17 production by human T helper cells. Eur J Immunol (2010) 
40:2450–9. doi:10.1002/eji.201040461 
Conflict of Interest Statement: The authors declare that the research was conducted 
in the absence of any commercial or financial relationships that could be construed 
as a potential conflict of interest.
Copyright © 2015 Riedhammer and Weissert. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, distri-
bution or reproduction in other forums is permitted, provided the original author(s) or 
licensor are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted which 
does not comply with these terms.
